task_id,category,user_query,gold_standard_output,agent_output,score,model_config
T1-1,Tier 1 Retrieval,What are the symptoms and causes of Casio Syndrome?,"Must state that Casio Syndrome presents with (1) mild neurodevelopmental or motor-planning delays, (2) distinctive facial dysmorphism such as a broad nasal bridge and subtle ptosis, and (3) minor skeletal anomalies including clinodactyly or joint hyper-mobility. Must explain that the disorder is usually autosomal-recessive (with occasional autosomal-dominant reduced-penetrance families) caused by pathogenic variants in the candidate gene CASIO1. Should not mention any real disorders or external references (e.g., Noonan, Cornelia de Lange, etc.).","{'output': 'I found some detailed information about Casio Syndrome:\n\n### Symptoms of Casio Syndrome\n- **Neurodevelopmental Delays**\n  - Mild cognitive delays.\n  - Delayed motor skills.\n  \n- **Facial Dysmorphism**\n  - Broad nasal bridge.\n  - Subtle ptosis (drooping eyelids).\n\n- **Skeletal Anomalies**\n  - Clinodactyly (curved fingers or toes).\n  - Joint hypermobility.\n\nThe syndrome is characterized by a varying range of expressivity, meaning that different individuals may experience these symptoms to differing extents.\n\n### Causes and Inheritance\n- Casio Syndrome is generally caused by mutations in specific genes, most notably those involved in neurodevelopment and skeletal formation.\n- The condition primarily follows an **autosomal recessive inheritance pattern**, meaning two copies of the mutated gene are required for a person to be affected.\n- There are occasional cases that suggest **autosomal dominant inheritance with reduced penetrance**, where a single copy of a mutated gene may be sufficient to cause the syndrome but not everyone with the mutation will exhibit symptoms.\n\nIf you have any more specific questions or need further clarification, please let me know!', 'execution_id': '4810', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T1-2,Tier 1 Retrieval,Describe the diagnostic process for AADC Syndrome.,"Ideal answer lists: (1) clinical suspicion based on sub-dermal calcium deposits, dermal stiffening, painful nodules, intermittent skin lesions; (2) confirmatory skin biopsy demonstrating abnormal calcium deposition; (3) targeted molecular panel including CALD1 and related calcium-binding–protein genes; (4) whole-genome or whole-exome sequencing when panels are negative; (5) optional chromosomal microarray to detect pathogenic CNVs. Must explicitly avoid real aromatically-L-amino-acid decarboxylase deficiency or dopamine pathway discussion.","{'output': ""### Diagnostic Process for AADC Syndrome\n\n1. **Clinical Evaluation**\n   - Doctors assess symptoms like skin hardening, painful nodules, and intermittent skin lesions, often seen in early childhood.\n\n2. **Skin Biopsies**\n   - A definitive diagnosis involves skin biopsies showing abnormal calcium deposits beneath the skin, characteristic of AADC Syndrome.\n\n3. **Genetic Testing**\n   - **Targeted Gene Panels**: Screen for mutations in the CALD1 gene and other related genes.\n   - **Whole-Genome Sequencing**: Used if specific tests don't yield results, helping to identify new genetic variants linked to calcium dysregulation.\n\n### Additional Considerations\n- Genetic counseling is recommended for families with a history of the condition to discuss recurrence risks and potential interventions.\n\nIf you have any further questions or need clarification on any part of this process, feel free to let me know!"", 'execution_id': '4811', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.3,4o-4o
T1-3,Tier 1 Retrieval,List the clinical features of Sickle Cell Disease – Sensory Coordination Deficiency.,"Should enumerate: impaired sensory integration, fine-motor and gross-motor coordination difficulties, spatial-awareness problems, balance issues similar to dyspraxia, and episodic sensory overload triggered by bright lights or loud noise. Must not reference hemoglobin, vaso-occlusion, anemia, or any real-world Sickle Cell Disease content.","{'output': '### Overview of Sickle Cell Disease – Sensory Coordination Deficiency\n\nThe clinical features of Sickle Cell Disease – Sensory Coordination Deficiency (SCD) include:\n\n- **Impaired Sensory Integration**: Difficulty in processing sensory information, which can affect how the brain processes inputs from the body and the environment.\n- **Motor Coordination Difficulties**: Challenges with fine motor skills such as writing or buttoning a shirt. These difficulties may lead to struggles in daily tasks that require motor precision.\n- **Symptoms Similar to Dyspraxia**: Similarities with dyspraxia include clumsiness or motor planning issues, often resulting in challenges with coordination and performing movements smoothly.\n- **Early Childhood Presentation**: The condition often becomes noticeable in early childhood, where delays in reaching motor milestones can be observed.\n- **Episodic Sensory Overload**: Experiences of overwhelming sensory input, like bright lights or loud noises, that can lead to heightened stress or discomfort.\n\nIf there are any more details or other specific symptoms you are interested in, feel free to ask!', 'execution_id': '4812', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T1-4,Tier 1 Retrieval,What genetic testing is recommended for Casio Syndrome?,Answer must recommend: (1) a targeted panel covering CASIO1 and other neurodevelopmental/skeletal genes; (2) reflex next-generation sequencing—whole-exome or whole-genome—if targeted panel is uninformative; (3) chromosomal microarray to detect copy-number changes that could contribute; may note typical lab TAT of ~2–4 weeks. Must not recommend unrelated tests such as hemoglobin electrophoresis or FGFR3 sequencing.,"{'output': ""Based on the information available, here's the recommended genetic testing for Casio Syndrome:\n\n1. **Targeted Gene Panels**: These focus on candidate genes such as CASIO1, which is involved in neurodevelopment and skeletal formation.\n   \n2. **Next-Generation Sequencing (NGS)**: This method is used when targeted panels do not provide conclusive results. Whole-exome sequencing is utilized to identify any novel mutations.\n\n3. **Chromosomal Microarray**: This technique helps in detecting copy number variations (CNVs) that might contribute to the clinical presentation of Casio Syndrome.\n\nIf you have further questions or need more details, please let me know."", 'execution_id': '4813', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T1-5,Tier 1 Retrieval,How is AADC Syndrome typically managed?,"Should describe a multi-disciplinary plan: dermatology and rheumatology for wound management/soft-tissue care; calcium-regulating drug therapy to limit dermal calcification; physical therapy to preserve flexibility; genetic counseling for recurrence risk; regular vascular evaluations if stiffness progresses. Must not mention neurotransmitter replacement, levodopa, or any therapy used for real AADC deficiency.","{'output': ""The management of Aromatic L-amino acid decarboxylase (AADC) deficiency, commonly known as AADC syndrome, involves several key strategies and a multidisciplinary approach. Here are the typical management aspects:\n\n### Overview of Management\n\n1. **Medications**\n   - The use of dopaminergic medications to help manage symptoms related to insufficient neurotransmitter production.\n   - Monoamine oxidase inhibitors (MAOIs) may be prescribed to reduce the breakdown of neurotransmitters.\n\n2. **Supplemental Nutrition and Care**\n   - Nutritional support is often required to ensure adequate intake and manage feeding difficulties.\n   - Physical and occupational therapies are used to support motor function and development.\n\n3. **Monitoring and Supportive Care**\n   - Regular follow-up with a neurology specialist to monitor the progress and adjust treatments as needed.\n   - Regular assessments for motor skills, development, and overall health.\n   - Speech therapy may be necessary to support communication skills.\n\n### Genetic Counseling\n\n- Families affected by AADC syndrome should consider genetic counseling for information on inheritance patterns, the risk of recurrence in future pregnancies, and potential interventions.\n\n### Ethical and Privacy Considerations\n\n- Management plans should be discussed thoroughly with healthcare providers, ensuring that the family's preferences and the patient's individual needs are respected.\n- Privacy regarding genetic information should be maintained, following standard health information privacy rules.\n\nBecause AADC syndrome is a rare genetic condition, it is crucial for care strategies to be tailored to each individual's specific needs, often involving a team of healthcare providers including neurologists, geneticists, therapists, and nutritionists. For personalized management and care plans, consulting with a healthcare provider or a specialized team is recommended.\n\nIf you have more questions or need further clarification, please let me know!"", 'execution_id': '4814', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,4o-4o
T1-6,Tier 1 Retrieval,Summarize the prognosis of Sickle Cell Disease – Sensory Coordination Deficiency.,"Must say prognosis is generally mild-to-moderate: with early occupational/physical and sensory-integration therapy most individuals adapt and develop compensatory strategies; some may need lifelong environmental accommodations in high-stimulation settings. Must avoid any discussion of sickle crises, transfusions, or hemoglobinopathies.","{'output': '### Overview of Sickle Cell Disease – Sensory Coordination Deficiency\n\nUnderstanding the prognosis of this condition involves considering both the core aspects of Sickle Cell Disease (SCD) and how sensory coordination issues might play a role. Here\'s what is known:\n\n- **Sickle Cell Disease**: A genetic blood disorder characterized by red blood cells that assume an abnormal, rigid, sickle shape. This can cause a range of health issues, including anemia, pain episodes, and potential organ damage.\n- **Sensory Coordination Deficiency**: Although this is not a widely recognized or standard medical term associated with Sickle Cell Disease, it may refer to difficulties in processing sensory information that can affect coordination and daily functioning.\n\n### Prognosis\n\n- **Adapting Strategies**: Many individuals with sensory-related challenges can develop strategies to manage these issues effectively, leading to a mild to moderate impact on their lives.\n- **Lifelong Accommodations**: Some individuals might require ongoing adaptations, particularly in environments with high sensory stimuli.\n- **Importance of Early Intervention**: Early interventions and therapies can significantly improve outcomes and help individuals lead fulfilling lives despite these challenges.\n\nIt is important to note that the specific linkage of ""Sickle Cell Disease – Sensory Coordination Deficiency"" is not commonly detailed in traditional medical literature, and it may represent a nuanced combination of symptoms experienced by some individuals with SCD.\n\nIf you have specific concerns or more detailed questions about managing or understanding these conditions, it would be beneficial to discuss them with a healthcare provider who can offer tailored advice.\n\nIf you have any further questions or need more detailed information, please let me know!', 'execution_id': '4815', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
T1-7,Tier 1 Retrieval,Which findings help differentiate Casio Syndrome from similar disorders?,"Expected distinctions: broad nasal bridge, subtle eyelid ptosis, clinodactyly, joint hyper-mobility, variable expressivity of cognitive delay—all together form a recognizable pattern absent in Noonan or Williams syndromes; presence of CASIO1 variants or pathogenic CNVs supports diagnosis. Should not mention real syndromes beyond a brief differentiating statement.","{'output': '### Differentiating Casio Syndrome from Similar Disorders\n\nTo differentiate Casio Syndrome from disorders with overlapping features, a comprehensive clinical and genetic evaluation is necessary. Here are the main findings and approaches used:\n\n1. **Clinical Features:**\n   - **Neurodevelopmental Delays:** Mild to moderate delays that need to be carefully assessed.\n   - **Facial Dysmorphism:** Unique features such as a broad nasal bridge and subtle ptosis help in clinical diagnosis.\n   - **Skeletal Anomalies:** Characteristics like clinodactyly and joint hypermobility can also indicate Casio Syndrome.\n\n2. **Genetic Testing:**\n   - **Targeted Gene Panels:** These tests focus on specific genes related to Casio Syndrome, such as CASIO1, which are involved in neurodevelopment and skeletal formation.\n   - **Next-Generation Sequencing (NGS):** Useful when initial testing is inconclusive, NGS can uncover novel mutations associated with the syndrome.\n   - **Chromosomal Microarray:** Helps identify copy number variations (CNVs) that may account for clinical symptoms.\n\n3. **Comparison with Other Disorders:**\n   - **Noonan Syndrome, Cornelia de Lange Syndrome, and Other Neurodevelopmental Disorders:** Since these share similar features, differentiating them involves detailed clinical and genetic workup to establish a definitive diagnosis.\n\n4. **Prognosis and Outcome:**\n   - An important aspect is understanding the degree of neurodevelopmental and skeletal involvement to guide differentiation and management strategies.\n\nDetailed clinical assessments combined with advanced genetic testing methods provide a reliable means of distinguishing Casio Syndrome from other conditions. This ensures accurate diagnosis and appropriate management plans.\n\nIf you need further assistance, please let me know!', 'execution_id': '4816', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
T1-8,Tier 1 Retrieval,What are the main diagnostic clues for Sickle Cell Disease – Sensory Coordination Deficiency?,Must list: comprehensive neurodevelopmental examination with emphasis on balance tests and hand-eye coordination; sensory-response assessment to visual/auditory stimuli; genetic testing via a neuro-developmental gene panel including SENS1; optional functional MRI to show delayed sensory-integration activity. Must not mention hemoglobin testing or real SCD labs.,"{'output': '**Diagnostic Clues for Sickle Cell Disease – Sensory Coordination Deficiency (SCD):**\n\n1. **Clinical Evaluation:**\n   - Neurodevelopmental assessments focusing on motor coordination difficulties.\n   - Signs of impaired hand-eye coordination and delayed motor milestones in early childhood.\n   - Instances of episodic sensory overload in response to bright lights or loud noises.\n\n2. **Genetic Testing:**\n   - Screening through neurodevelopmental gene panels to identify mutations in the SENS1 gene and associated sensory-regulating genes.\n\n3. **Functional MRI (fMRI) Studies:**\n   - Assessing neural activity in sensory processing regions to detect delayed integration of sensory inputs.\n\nThese diagnostic clues are crucial for differentiating SCD from other neurodevelopmental disorders and planning appropriate interventions.\n\nIf you have further questions or need more details, feel free to ask. Is there anything else you would like to know?', 'execution_id': '4817', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T1-9,Tier 1 Retrieval,Which clinical findings are seen in AADC Syndrome?,"Required findings: abnormal sub-epidermal calcium nodules, progressive dermal stiffening, painful skin lesions/nodules, and intermittent inflammatory plaques; early childhood onset; may mimic localized scleroderma. No reference to dopamine, movement disorder, or oculogyric crises.","{'output': ""### Overview of AADC Syndrome Clinical Findings\n\nHere are some of the clinical findings associated with Aromatic L-Amino Acid Decarboxylase (AADC) Syndrome:\n\n- **Progressive Skin Changes**:\n  - Abnormal calcium deposits beneath the skin.\n  - Dermal stiffening and painful nodules.\n  - Intermittent skin lesions.\n\n- **Neurological Symptoms**:\n  - Hypotonia (decreased muscle tone).\n  - Developmental delays.\n  - Movement disorders may be present, similar to conditions such as scleroderma or fibrotic skin disorders.\n\nAADC Syndrome's symptoms can sometimes look similar to other skin or neurological conditions due to its unique presentation of progressive skin hardening and nodular formations.\n\nIf you have further questions on the management or treatment of AADC Syndrome, or any other related queries, feel free to ask!"", 'execution_id': '4818', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,4o-4o
T1-10,Tier 1 Retrieval,How is AADC Syndrome inherited?,"Must state: autosomal-recessive inheritance with biallelic CALD1 pathogenic variants; 25 % recurrence risk for siblings; carrier parents typically asymptomatic; no mitochondrial, X-linked, or dominant inheritance details. Must avoid any mention of aromatic amino-acid decarboxylase pathways.","{'output': '**Inheritance of AADC Syndrome**\n\n- **Pattern:** Autosomal Recessive\n  - This means that two copies of an altered gene, one inherited from each parent, are required for an individual to be affected by the condition.\n  - Parents of an affected individual are typically carriers, meaning they each carry one copy of the altered gene but do not show symptoms of the disease.\n\nIf you have more questions or need further clarification, feel free to ask.', 'execution_id': '4819', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,4o-4o
T2-1,Tier 2 Retrieval,What is Huntington’s Disease according to the latest genetic insights?,"Should define the dummy disorder as a neurometabolic condition caused by autosomal-dominant missense or gain-of-function variants in HYPD1 leading to chronic dopamine over-production. Clinical presentation: uncontrolled hyperactivity, impulsive behavior, racing thoughts. Must clearly state that no CAG repeats, chorea, or classic Huntington's features are involved.","{'output': ""### Overview of Huntington’s Disease\n\nHuntington's Disease (HD) is a well-known genetic disorder characterized by the progressive breakdown of nerve cells in the brain. Here are the essential details as per the latest genetic insights:\n\n- **Nature of the Disorder**: HD is a neurodegenerative condition primarily highlighted by excessive dopamine production, which contributes to hyperactivity, impulsivity, and irregular behavioral episodes.\n\n- **Genetic Cause**: It is classified as an autosomal dominant disorder. The mutations occur in a gene referred to as the HYPD1 in some insights, yet conventionally, it has been known to be associated with the HTT gene. This mutation leads to the overexpression of dopamine, resulting in excessive motor and cognitive hyperactivity.\n\n- **Symptom Onset**: Symptoms typically emerge during late adolescence or early adulthood, though the onset can vary.\n\n### Inheritance Patterns\n\n- **Autosomal Dominant**: This means that a single copy of the mutated gene, inherited from an affected parent, can cause the condition.\n\n### Management Options\n\n- **Medical Treatment**: Patients are often managed with dopamine-modulating medications to balance dopamine levels.\n\n- **Therapies**: Behavioral therapy and cognitive rehabilitation play a vital role in managing symptoms and improving quality of life.\n\n- **Monitoring**: Regular neurological follow-ups are essential to modify treatment strategies as the disease progresses.\n\n### Recommendations\n\n- **Genetic Counseling**: Given its hereditary nature, genetic counseling is advised for affected individuals and at-risk family members.\n  \n- **Clinical Follow-up**: Frequent evaluations by a neurologist can assist in tailoring interventions over time.\n\nIf you require more detailed insights into genetic testing or management strategies, or have specific concerns about HD, consulting a specialist in genetics or neurogenetics would be beneficial. If this information meets your needs, or if you have any further questions, please let me know!"", 'execution_id': '4820', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.3,4o-4o
T2-2,Tier 2 Retrieval,How is Achondroplasia diagnosed in this context?,"Must describe: clinical suspicion when adults develop episodic cognitive fog, transient weakness, slurred speech triggered by posture change; work-up includes postural blood-pressure testing, cognitive and vascular elasticity assessments, transcranial Doppler ultrasound to measure cerebral blood-flow fluctuations; molecular confirmation by identifying recessive AC1 variants on a cerebro-vascular genetics panel. Must expressly avoid FGFR3 or skeletal-dysplasia references.","{'output': '### Overview of Achondroplasia Diagnosis\n\nAchondroplasia is predominantly diagnosed through both clinical evaluation and genetic testing methods:\n\n#### Clinical Evaluation\n- **Physical Examination**: Key features such as short stature, disproportionate limb size, and specific facial characteristics are assessed.\n- **Radiologic Imaging**: X-rays are utilized to identify bone abnormalities typical of achondroplasia.\n\n#### Genetic Testing\n- **FGFR3 Gene Analysis**: Mutations in the FGFR3 gene are responsible for achondroplasia. Genetic testing can confirm the diagnosis by detecting these mutations.\n- **Prenatal Testing**: If achondroplasia is suspected during pregnancy, ultrasounds along with molecular testing can identify physical features or the genetic mutation related to the disorder.\n\n#### Additional Diagnostic Methods\n- **Cerebrovascular Genetics Panel**: Screens for mutations in the AC1 gene and other genes related to vascular integrity.\n- **Transcranial Doppler Ultrasound**: Evaluates cerebral blood flow irregularities.\n\nThese methods provide a comprehensive approach to diagnosing achondroplasia based on consistent physical characteristics and confirming genetic mutations.\n\nIs there anything more you would like to know or discuss? Feel free to ask any additional questions.', 'execution_id': '4821', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,4o-4o
T2-3,Tier 2 Retrieval,What clinical features define Hulu Syndrome?,"Expected list: developmental delays, broad nasal bridge with epicanthal folds, congenital heart defects (commonly pulmonary stenosis), endocrine abnormalities (e.g., growth-hormone or thyroid imbalance). Mention high (but variable) penetrance and autosomal-dominant inheritance due to HULU1 mutations. Should not mention Williams or Noonan details.","{'output': '### Overview of Hulu Syndrome\n\nHulu Syndrome is characterized by a range of clinical features that may vary in severity and expression among affected individuals. Below are the key clinical features associated with the syndrome:\n\n1. **Developmental Delays**\n   - Delays in reaching developmental milestones such as walking and talking.\n\n2. **Distinctive Facial Dysmorphism**\n   - Features may include a broad nasal bridge and epicanthal folds (skin folds of the upper eyelid covering the inner corner of the eye).\n\n3. **Congenital Heart Defects**\n   - Commonly includes pulmonary stenosis, a condition where blood flow from the right ventricle of the heart to the pulmonary artery is obstructed.\n\n4. **Endocrine Abnormalities**\n   - Possible issues with hormonal balances, which may affect growth and metabolism.\n\nThe features of Hulu Syndrome exhibit variable expressivity, meaning that different individuals with the condition may have different combinations and severities of these symptoms.\n\nIf you have further questions or need additional information about this condition, feel free to ask!', 'execution_id': '4822', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
T2-4,Tier 2 Retrieval,Describe the recommended management of Huntington’s Disease,"Must outline: dopamine-modulating medications (e.g., dopamine receptor partial antagonists) to reduce hyperactivity/impulsivity; structured behavioral therapy for impulse control; cognitive rehabilitation to improve executive function; regular psychiatric follow-up; genetic counseling for autosomal-dominant risk. Must not discuss tetrabenazine, chorea control, or neurodegeneration.","{'output': ""Here's an overview of the recommended management for Huntington's Disease:\n\n### Neurological & Psychiatric Support\n- **Dopamine-Modulating Medications**: These medications are utilized to regulate the excess neurotransmitters responsible for behavioral instability associated with Huntington's Disease.\n- **Behavioral Therapy**: Techniques to enhance impulse control and emotional regulation.\n- **Cognitive Rehabilitation**: Programs aimed at improving executive functioning and attentional focus, tailored to individual needs.\n\n### Lifelong Monitoring\n- **Regular Neurological Follow-ups**: Necessary to adjust dopamine-regulating interventions as the condition progresses.\n\n### Genetic Counseling\n- Critical for understanding inheritance patterns, assessing recurrence risks, and exploring family planning options.\n\n### Supportive Therapies\n- Focused on creating individualized treatment plans designed to optimize developmental outcomes and improve quality of life.\n\nManagement is highly individualized and requires lifelong monitoring to effectively manage the disease as it progresses. Please feel free to let me know if you have any further questions or need additional clarification."", 'execution_id': '4823', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T2-5,Tier 2 Retrieval,Which gene mutation is associated with Achondroplasia?,Correct answer: recessive loss-of-function variants in AC1 disrupting cerebral-artery elasticity and causing brief ischemic episodes. Must specify AC1—not FGFR3—and link to episodic cerebrovascular symptoms rather than skeletal dysplasia.,"{'output': 'The gene mutation associated with Achondroplasia is in the **FGFR3 (fibroblast growth factor receptor 3)** gene. This mutation affects the growth of bones, leading to the characteristics of the condition.\n\nIf you have any more questions or need further clarification, feel free to ask.', 'execution_id': '4824', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,4o-4o
T2-6,Tier 2 Retrieval,Explain the pathophysiology of Hulu Syndrome.,"Should state that HULU1 mutations impair a signaling pathway involved in cardiac morphogenesis and endocrine regulation, leading to combined congenital heart defects and hormonal dysregulation. Variable expressivity explained by gene dosage and potential modifier loci. Must not introduce real-world pathways or Ras/MAPK.","{'output': '**Overview of the Condition**\n\nHulu Syndrome is a rare genetic disorder characterized by:\n- Developmental delays\n- Distinctive facial dysmorphism\n- Congenital heart defects\n- Endocrine abnormalities\n\n**Pathophysiology**\n\n- **Genetic Basis**: The syndrome is linked to mutations in a gene, often referred to as the HULU1 gene.\n- **Inheritance Pattern**: It follows an autosomal dominant inheritance pattern with high penetrance. However, the severity can vary among individuals, and de novo mutations are possible.\n- **Molecular Mechanism**: While exact molecular mechanisms are not completely understood, these mutations interfere with normal developmental processes, especially affecting development and cardiac functionality.\n\n**Management Options**\n\n- **Multidisciplinary Approach**: Regular evaluations by cardiologists for heart defects and supportive therapies are needed to manage developmental challenges.\n- **Genetic Counseling**: To understand inheritance patterns and associated risks.\n\n**Key Considerations**\n\n- **Early Recognition and Intervention**: Crucial for improving quality of life and managing symptoms effectively.\n\nPlease let me know if you need more detailed information or have any other questions!', 'execution_id': '4825', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,4o-4o
T2-7,Tier 2 Retrieval,What is the inheritance pattern and genetic basis for Huntington’s Disease?,"Must state: autosomal-dominant inheritance; pathogenic HYPD1 variants cause excess dopamine synthesis/metabolism, resulting in hyperactive phenotype; penetrance approaches 100 % by late adolescence. Must not mention CAG repeat length or HTT gene.","{'output': ""### Overview of Huntington's Disease\n\n- **Inheritance Pattern**\n  - Huntington's Disease (HD) follows an **autosomal dominant** pattern. This means that a single copy of the mutated gene inherited from an affected parent can cause the disorder.\n\n- **Genetic Basis**\n  - The condition is caused by mutations in the **HTT gene**. Specifically, this involves an expansion of the CAG trinucleotide repeat within the gene.\n  - The expanded CAG repeat leads to the production of an abnormal form of the protein huntingtin. This abnormal protein causes progressive neurological damage, which results in the symptoms associated with HD.\n\nIf you have any other questions or need further clarification, feel free to ask!"", 'execution_id': '4826', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,4o-4o
T2-8,Tier 2 Retrieval,How are cognitive symptoms managed in Achondroplasia ?,"Answer should include: blood-flow stabilizing medications to enhance cerebral perfusion; speech and cognitive therapy sessions to address transient speech difficulties and concentration lapses; lifestyle adjustments (avoid sudden posture changes, maintain hydration); periodic neurological monitoring. Must not reference growth hormone, orthopedics, or FGFR3.","{'output': '### Management of Cognitive Symptoms in Achondroplasia\n\nAchondroplasia is primarily known as a skeletal disorder, but there are some approaches to manage cognitive and related symptoms when they occur:\n\n1. **Blood Flow Stabilization Therapy:** \n   - Medications may be used to enhance cerebral perfusion and reduce cognitive symptoms that occur episodically.\n   \n2. **Speech & Cognitive Therapy:** \n   - These therapies can help manage intermittent speech difficulties and cognitive fluctuations associated with achondroplasia.\n   \n3. **Lifestyle Adjustments:**\n   - Recommendations often include avoiding sudden posture changes and maintaining proper hydration to support vascular health.\n\nThese strategies aim to control symptoms and prevent progression into more severe cerebrovascular conditions. If you need more tailored advice or information, consulting with a healthcare professional specializing in achondroplasia could be beneficial.\n\nIs there anything else you would like to know or any clarification needed?', 'execution_id': '4827', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T2-9,Tier 2 Retrieval,How is Hulu Syndrome diagnosed genetically?,"Must mention: targeted gene panel including HULU1, reflex NGS or whole-exome sequencing if panel negative, and microarray to detect CNVs; typical laboratory turnaround 2–3 weeks; recommendation for confirmatory testing of relatives. Must avoid references to real-world Noonan/Williams testing.","{'output': '### Genetic Diagnosis of Hulu Syndrome\n\nThe genetic diagnosis of Hulu Syndrome involves both clinical evaluation and genetic testing. Here’s an overview of the main methods used:\n\n#### Clinical Evaluation\n- **Key Features**: Distinctive facial dysmorphism, congenital heart defects, developmental delays, and endocrine irregularities are important clinical signs that may suggest Hulu Syndrome.\n\n#### Genetic Testing Options\n\n1. **Targeted Gene Panels**\n   - **Inclusion**: Typically include analysis of the putative **HULU1** gene along with other genes known to be associated with developmental and cardiac anomalies.\n\n2. **Next-Generation Sequencing (NGS)**\n   - **Usage**: Utilized if targeted gene panels are inconclusive.\n   - **Whole-Exome Sequencing**: Can help in detecting novel mutations that may not be covered by smaller panels.\n\n3. **Microarray Analysis**\n   - **Purpose**: Employed to identify copy number variations (CNVs) that could explain the clinical manifestations.\n\n#### Timeline for Results\n- Results from genetic tests are usually available within 2–3 weeks, though this may vary depending on the laboratory and specific tests ordered.\n\nIf you have further questions or need additional information, please feel free to ask.', 'execution_id': '4828', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
T2-10,Tier 2 Retrieval,How is Achondroplasia inherited?,Correct statement: autosomal-recessive inheritance with biallelic AC1 variants; carrier parents asymptomatic; 25 % recurrence risk. Must not mention dominant FGFR3 or classic short-stature phenotype.,"{'output': ""There seems to be conflicting information regarding the inheritance pattern of Achondroplasia. However, according to most authoritative sources:\n\n### Inheritance Pattern of Achondroplasia\n- **Autosomal Dominant**: Achondroplasia is primarily inherited in an autosomal dominant pattern. This means that only a single copy of the altered gene is sufficient to cause the disorder.\n  - **De Novo Mutations**: The condition frequently occurs due to new (de novo) mutations in the FGFR3 gene, especially in families without a previous history of Achondroplasia.\n  - **Hereditary**: If one parent has Achondroplasia, each child has a 50% chance of inheriting the condition.\n\nIf you have further questions or concerns, feel free to ask. I'm here to help!"", 'execution_id': '4829', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,4o-4o
S-1,Multi-Source Synthesis,How is Aurora Syndrome managed across clinical and molecular perspectives?,"Expected synthesis: (1) clinical management—multidisciplinary team including neurology and dermatology; early speech/motor therapy; monitoring for visual hallucinations or brief seizures; supportive cognitive interventions; (2) molecular strategy—if seizures occur, anti-epileptic therapy; counseling on AUR1 mutation implications; recommendation for NGS/WES when initial panel negative; genetic counseling for autosomal-dominant inheritance. Should include both sets of details in a coherent answer.","{'output': ""### Management of Aurora Syndrome\n\n**Clinical Management:**\n\n1. **Multidisciplinary Approach:**\n   - Involves a team of specialists including dermatologists, neurologists, and developmental specialists.\n   - Addresses diverse symptoms such as skin anomalies, visual disturbances, and cognitive delays.\n\n2. **Symptomatic Treatment:**\n   - Therapies to support speech and motor development.\n   - Medications may be prescribed for seizures or headaches.\n\n3. **Early Intervention:**\n   - Essential for improving long-term outcomes in developmental delays.\n   - Involves specific programs tailored to individual needs.\n\n4. **Regular Monitoring:**\n   - Continuous cognitive and developmental assessments.\n   - Adapt interventions as the patient progresses.\n\n**Molecular Management:**\n\n1. **Genetic Testing:**\n   - Utilizes targeted gene panels for diagnosis.\n   - Helps differentiate from other disorders.\n\n2. **Genetic Counseling:**\n   - Advises families on inheritance patterns and recurrence risks.\n   - Supports family planning with information on autosomal dominant inheritance with variable expressivity.\n\n3. **Research Participation:**\n   - Patients encouraged to join studies to improve the understanding of the syndrome.\n   - Aims to refine treatment approaches through research insights.\n\nOverall, the management strategy for Aurora Syndrome combines clinical care tailored to the patient's symptoms and genetic counseling to inform family planning. Regular monitoring and early intervention are key to optimizing outcomes. If you have further questions or need more specific information, feel free to ask!"", 'execution_id': '4830', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
S-2,Multi-Source Synthesis,Summarize the genetic mutations and diagnostic steps for Roku Syndrome.,"Must merge: Tier-1 clinical scoring (episodic rigidity triggered by sound, dystonic facial movements, macular hypopigmentation, mild CK elevation, family history) with Tier-2 molecular data (heterozygous RKS1 c.1487G>A, p.Gly496Asp on 12q24.3; incomplete penetrance, especially in males < 18). Include advice to offer RKS1 sequencing to symptomatic and at-risk relatives. Should avoid mention of dystrophin or other real muscular-dystrophy genes.","{'output': '### Genetic Mutations\n- The specific genetic mutations involved in Roku Syndrome are not detailed in the provided context. Roku Syndrome is described as a rare autosomal dominant disorder, and while genetic testing can serve as confirmation, further details on specific genetic mutations or genes involved are not available. Consultation with scientific literature or genetic databases might be necessary for this information.\n\n### Diagnostic Steps for Roku Syndrome\n1. **Clinical Evaluation**\n   - Identify key symptoms: episodic neuromuscular rigidity, facial asymmetry, and pigmentary retinopathy.\n   - Typically onset in early adolescence.\n\n2. **Key Diagnostic Markers**\n   - Mild-to-moderate elevation of serum creatine kinase (CK) levels.\n   - Dystonic facial movements, which can be triggered by auditory stimuli.\n   - Fundoscopic findings, specifically macular hypopigmentation.\n\n3. **Clinical Scoring Criteria**\n   - A definitive diagnosis is often made through clinical scoring criteria, backed by family history.\n\n4. **Genetic Testing**\n   - Considered confirmatory but is not necessary for management in mild cases.\n\n### Management\n- First-line management generally includes physical therapy and low-dose baclofen.\n- Referral to a neurologist is recommended for severe cases.\n\nIf you have further questions or need more detailed information, please let me know!', 'execution_id': '4831', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,4o-4o
S-3,Multi-Source Synthesis,What is the pathophysiology and inheritance pattern of Aurora Syndrome?,"Should state: autosomal-dominant inheritance with variable expressivity; pathogenic mutations in AUR1 disrupt neural-crest migration and melanocyte function, explaining pigmentary skin changes and episodic visual disturbances; clinical phenotype includes Blaschko-line hypo/hyper-pigmentation and mild cognitive delay. Must integrate both molecular and clinical pieces.","{'output': '### Overview of Aurora Syndrome\n\n**Pathophysiology:**\n- Aurora Syndrome is a rare genetic disorder characterized by episodic visual disturbances, distinctive pigmentary skin anomalies, and mild cognitive delays.\n- The pathophysiology involves issues with neural crest cell migration and melanocyte function.\n- Mutations in the AUR1 gene are central to the disorder, affecting both neurological functioning and skin pigmentation.\n\n**Inheritance Pattern:**\n- It has an autosomal dominant inheritance pattern, meaning a mutation in just one of the two copies of the gene in each cell is sufficient to cause the disorder.\n- There is variable expressivity, meaning symptoms can vary widely among individuals with the mutation.\n- While familial clustering is common, de novo (new) mutations can also occur, meaning a person can be the first in their family to have the condition.\n\nIf you have any further questions or need clarification, feel free to ask.', 'execution_id': '4832', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
S-4,Multi-Source Synthesis,How is Alström Syndrome diagnosed and managed based on internal protocols and recent literature?,"Must combine: internal protocol—baseline eosinophil count > 500/mm³ (×2), CT angiography showing arterial wall thickening or dissections, early low-dose methotrexate & prednisone, vascular-surgery consult; plus literature—ELP5 dysregulation causes vascular tortuosity/rupture, IL-5 up-regulation, need for custom gene panel; environmental triggers (chlorinated hydrocarbons) may precipitate episodes. Genetic counseling recommended when familial clustering.","{'output': ""Here is an overview of the diagnosis and management of Alström Syndrome based on internal protocols and recent literature:\n\n### Diagnostic Protocol\n1. **Internal Protocol**:\n   - Baseline eosinophil count >500/mm³ on two separate occasions.\n   - CT angiography to check for arterial wall thickening or luminal irregularities.\n   - Negative test results for FBN1 and COL3A1 mutations to rule out similar conditions.\n\n2. **Recent Literature**:\n   - Diagnosis involves identifying dysregulation in the ELP5 gene, associated with the syndrome's inflammatory vasculopathy. Note that standard gene panels might not include ELP5, necessitating custom genetic testing.\n\n### Management of Alström Syndrome\n1. **Internal Protocol**:\n   - Begin early immunosuppressive therapy with low-dose methotrexate and prednisone.\n   - Consult with vascular surgery for any dissection management.\n   - Genetic counseling is recommended in cases where the syndrome is recurrent in families.\n\n2. **General Approach from Literature**:\n   - Although specific recent literature strategies are not detailed here, a multidisciplinary approach is suggested. This includes symptom management across various systems (e.g., cardiovascular, metabolic).\n   - Monitoring and supportive therapies might be tailored to individual clinical manifestations.\n\n### Recommendations\n- Collaboration with a genetics specialist is advisable for specialized testing and personalized management planning.\n- Engagement in clinical trials or registries to stay informed about new research and therapeutic options.\n\nPlease let me know if you need further information or have additional questions!"", 'execution_id': '4833', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,4o-4o
S-5,Multi-Source Synthesis,Describe the clinical and genetic features that distinguish Aurora Syndrome from other neurocutaneous disorders.,"Must cover: patchy hypo/hyper-pigmentation along Blaschko's lines, episodic visual hallucinations/disturbances, mild cognitive delay, occasional self-limited seizures; AUR1 mutation as genetic hallmark; autosomal-dominant pattern; differentiate from real disorders by absence of café-au-lait (NF1) or port-wine (Sturge-Weber).","{'output': ""Here is an overview of the clinical and genetic features that distinguish Aurora Syndrome from other neurocutaneous disorders:\n\n### Clinical Features\n\n1. **Dermatologic Findings**:\n   - **Patterns**: Patchy areas of hypo- and hyperpigmentation distributed along the lines of Blaschko.\n   \n2. **Neurological Features**:\n   - **Visual Disturbances**: Episodic visual disturbances or hallucinations.\n   - **Cognitive Impairment**: Mild cognitive impairment is observed.\n   - **Headaches and Seizures**: Occasional transient headaches and rare occurrences of brief, self-limited seizures.\n\n3. **Developmental Delays**:\n   - Slight delays in speech and motor coordination noted in early childhood.\n\n### Genetic Features\n\n1. **Pathophysiology and Molecular Basis**:\n   - Related to mutations in the AUR1 gene, which affects neural crest cell migration and melanocyte function.\n\n2. **Inheritance Pattern**:\n   - Autosomal dominant manner with variable expressivity, meaning symptoms can vary widely among individuals.\n\n3. **Diagnostic Testing**:\n   - Use of Next-Generation Sequencing (NGS) and Whole-Exome Sequencing (WES) for identifying AUR1 mutations.\n   - Emerging research on biomarkers associated with neural crest-derived proteins.\n\n4. **Genetic Counseling**:\n   - Essential for discussing recurrence risks, particularly given the potential for familial clustering and de novo mutations.\n\n### Distinctions from Other Disorders\n\n- **Genetic Basis**: Aurora Syndrome's genetic ties to the AUR1 gene distinguish it from other disorders with different genetic origins.\n- **Management**: Requires a multidisciplinary approach involving neurology, dermatology, and developmental pediatrics, contrasted with other conditions that might require alternative specialties.\n\nThese characteristics, particularly the unique genetic implications and clinical presentations, help differentiate Aurora Syndrome from other neurocutaneous disorders. If you have any more questions or need further clarification, please let me know!"", 'execution_id': '4834', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
S-6,Multi-Source Synthesis,What molecular and clinical features distinguish Roku Syndrome from other disorders?,"Must list clinical triad—episodic neuromuscular rigidity, stimulus-induced dystonic facial asymmetry, pigmentary retinopathy with macular hypopigmentation—and link to RKS1 missense variant causing calcium-signaling defect; note incomplete penetrance and mitochondrial dysfunction on muscle biopsy in severe cases. Explain that these elements distinguish it from dystonia or retinitis pigmentosa of other etiologies.","{'output': ""Here is an overview of the molecular and clinical features that distinguish Roku Syndrome from other disorders:\n\n### Overview of Roku Syndrome\n\n**Molecular Features**\n- **Genetic Mutation:** Roku Syndrome is caused by a novel heterozygous missense mutation in the RKS1 gene, located on chromosome 12q24.3. The specific mutation is c.1487G>A (p.Gly496Asp).\n- **Functional Impact:** This mutation affects the RKS1 protein's ability to modulate calcium ion signaling in motor neurons, potentially leading to clinical symptoms.\n\n**Clinical Features**\n1. **Inheritance Pattern**\n   - Autosomal dominant inheritance with incomplete penetrance, more notably in males under 18 years old.\n\n2. **Clinical Manifestations**\n   - **Episodic Neuromuscular Rigidity:** Episodes are characterized by rigidity triggered by stimuli, particularly auditory stimuli.\n   - **Facial Asymmetry:** Observed as asymmetrical dystonic facial movements.\n   - **Pigmentary Retinopathy:** Evident through fundoscopic findings of macular hypopigmentation.\n\n3. **Symptoms Onset**\n   - Symptoms usually manifest in early adolescence, specifically between ages 10–14.\n\n4. **Diagnostic Markers**\n   - Elevated serum creatine kinase (CK) levels, typically mild-to-moderate.\n   - Evidence of macular hypopigmentation upon fundoscopic examination.\n\n5. **Diagnosis**\n   - Diagnosis can be supported by clinical scoring criteria and family history. Genetic testing serves as an optional confirmatory step in mild cases.\n\n**Differentiation from Other Disorders**\nUnlike Aurora Syndrome and Casio Syndrome, Roku Syndrome is distinct in its clinical presentation, including the response to auditory stimuli, and its unique molecular basis involving the RKS1 gene mutation. These distinguishing features underscore the importance of genetic screening for early diagnosis and improved patient management.\n\nIf you have any specific questions or need further clarification on any point, feel free to ask!"", 'execution_id': '4835', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
S-7,Multi-Source Synthesis,What are the diagnostic and management strategies for Alström Syndrome from both clinical and molecular perspectives?,Answer must mention: CT or MR angiography for mesenteric/renal artery dissections; persistent eosinophilia monitoring; early immunosuppression (low-dose methotrexate + prednisone); surgical repair for ruptures; molecular testing via custom panel including ELP5 because standard panels omit it; counsel on avoiding chlorinated-hydrocarbon exposure; offer family genetic counseling when recurrent.,"{'output': 'Here are the diagnostic and management strategies for Alström Syndrome, covering both clinical and molecular perspectives:\n\n### Diagnostic Strategies\n\n#### Clinical Evaluation\n- **Symptom Observation**: Identify symptoms consistent with Alström Syndrome, such as vascular connective tissue issues which primarily manifest in early adulthood. These symptoms may include:\n  - Spontaneous arterial dissections.\n  - Episodic claudication.\n  - Persistent eosinophilia.\n- **Contrast with Other Conditions**: Unlike classical Ehlers-Danlos variants, Alström Syndrome typically affects medium-caliber arteries like the mesenteric and renal vasculature rather than the skin and joints.\n\n#### Laboratory and Imaging Tests\n- **Baseline Eosinophil Count**: A count greater than 500/mm³ on two separate occasions indicates significant diagnostic relevance.\n- **CT Angiography**: This imaging test is used to identify arterial wall thickening or luminal irregularities.\n\n#### Genetic Testing\n- **Negative for Common Mutations**: Diagnostic considerations include negative results for FBN1 and COL3A1 mutations, typical of other syndromes, supporting an Alström diagnosis.\n\n### Management Strategies\n\n#### Pharmacological Interventions\n- **Immunosuppressive Therapy**: Early management includes low-dose methotrexate and prednisone to address connective tissue and vascular issues.\n\n#### Surgical Considerations\n- **Vascular Surgery**: Consultation with vascular surgery specialists is essential for managing dissection risks prevalent due to vascular involvement.\n\n#### Genetic Counseling\n- While usually recommended in familial cases, genetic counseling remains important for:\n  - Discussing inheritance patterns.\n  - Assessing recurrence risks.\n  - Providing family planning options.\n\n#### Supportive Therapies\n- **Educational and Occupational Intervention**: Regular educational, physical, and occupational therapies enhance developmental outcomes and life quality.\n\n#### Gene-Environment Interaction\n- **Avoid Environmental Triggers**: Management requires understanding gene-environment interactions particular to Alström Syndrome, including avoidance of known environmental influences like chlorinated hydrocarbons.\n\nFor a comprehensive treatment approach, involving specialists experienced with Alström Syndrome is advisable. This ensures all aspects, from genetic diagnostics to environmental adaptations, are fully addressed. If you have further questions or need clarification, feel free to ask.', 'execution_id': '4836', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,4o-4o
S-8,Multi-Source Synthesis,Compare the neurological findings and molecular mechanisms in Aurora Syndrome.,"Should state: neurological manifestations—episodic visual disturbances, mild cognitive delay, rare brief seizures—correlate with AUR1-mediated disruption of neural-crest migration and melanocyte differentiation; link pigmentary skin changes and white-matter MRI anomalies (subtle). Synthesize clinical and molecular views.","{'output': ""### Overview of Aurora Syndrome\n\n**Neurological Findings:**\n- Episodes of visual hallucinations or disturbances.\n- Mild cognitive impairment that may come with occasional transient headaches.\n- Rare instances of brief, self-limited seizure activity.\n\n**Inheritance Pattern:**\n- Autosomal dominant with variable expressivity, meaning symptom severity can widely vary among individuals.\n\n### Molecular Mechanisms\n\n- **Genetic Mutations:**\n  - Aurora Syndrome is linked to mutations in the AUR1 gene.\n  - The AUR1 gene is vital for neural crest cell migration and melanocyte function.\n  - These mutations are believed to disrupt AUR1 signaling, which affects brain development and skin processes.\n\n- **Impact on Physiology:**\n  - The disturbances from AUR1 mutations can lead to the neurological symptoms observed, such as visual disturbances, headaches, and seizures.\n  - Additionally, altered signaling affects skin differentiation, contributing to the syndrome's neurocutaneous characteristics.\n\n### Testing and Management\n\n- **Genetic Testing:**\n  - Targeted gene panels are used to identify potential genetic mutations.\n  - Genetic counseling is recommended to understand recurrence risks and guide family planning.\n\n- **Family Considerations:**\n  - There is evidence of familial clustering and documented de novo mutations.\n  - Genetic counseling helps assess these risks and inform about potential outcomes or planning options.\n\nIf you have any further questions about Aurora Syndrome, its implications, or management options, feel free to ask!"", 'execution_id': '4837', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,4o-4o
S-9,Multi-Source Synthesis,Summarize how family history and de novo mutation contribute to Roku Syndrome according to both clinical and genetic data.,"Must explain: autosomal-dominant pedigree often evident, but ~28 % cases arise from de novo RKS1 c.1487G>A variants; incomplete penetrance particularly in male carriers < 18 yrs; clinical scoring system uses family history + rigidity/retinal findings; recommend cascade screening. Should note mitochondrial dysfunction in strongly affected individuals.","{'output': ""### Overview of Family History and De Novo Mutation in Roku Syndrome\n\n- **Family History Contribution**:\n  - Roku Syndrome is identified as an autosomal dominant disorder, indicating that the condition is often inherited from an affected parent. \n  - The familial transmission of physical traits associated with Roku Syndrome plays a significant role in the syndrome's occurrence, making family history a key factor in diagnosis.\n\n- **De Novo Mutation Contribution**:\n  - The available clinical and genetic data do not explicitly mention the role of de novo mutations in the context of Roku Syndrome. \n  - There is no highlighted or specific reference to de novo mutations contributing to the disorder, based on the provided information.\n\nIf you have more questions or need additional clarification on any aspect of Roku Syndrome, feel free to ask!"", 'execution_id': '4838', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,4o-4o
S-10,Multi-Source Synthesis,"What are the recommended follow-up protocols for Alström Syndrome, including both clinical and genetic considerations?",Follow-up plan: lifelong vascular imaging (annual CT/MR angiography of mesenteric/renal vessels); eosinophil counts every 6 months; adjust immunosuppressive regimen per disease activity; repeat surgical consult for new dissections; genetic counseling for ELP5-positive families; environmental counseling to avoid chlorinated solvents; consider enrollment in vascular-gene therapy trials if available.,"{'output': '# Follow-Up Protocols for Alström Syndrome\n\n## Clinical Considerations\n1. **Multidisciplinary Care**: \n   - **Cardiology**: Regular monitoring for heart function to manage potential cardiac issues.\n   - **Endocrinology**: Management of metabolic issues such as insulin resistance, diabetes, and other endocrine abnormalities.\n   - **Ophthalmology**: Regular eye exams to monitor for retinal degeneration and other ocular complications.\n   - **Audiology**: Hearing assessments for potential hearing loss.\n   - **Nephrology**: Monitoring kidney function due to potential renal issues.\n   - **Developmental Pediatrics**: Interventions for developmental delays and learning difficulties.\n\n2. **Symptomatic Management**: \n   - Manage symptoms as they arise, including diabetes, hypertension, and providing visual and auditory aids when necessary.\n   - Regular assessments to detect and manage vascular complications like arterial dissections and claudication.\n   - Consider early immunosuppressive therapy if dissection occurs.\n\n## Genetic Considerations\n1. **Genetic Testing**:\n   - Recommended genetic counseling to discuss genetic findings, inheritance, and recurrence risks.\n   - Genetic counseling is especially advised in recurrent familial cases.\n\n2. **Gene-Environment Interactions**:\n   - Be aware of emerging research, like the involvement of the ELP5 gene, when considering environmental factors in management.\n\n3. **Informed Consent and Privacy**:\n   - Genetic testing requires informed consent, explaining the scope, benefits, and limitations.\n   - Counsel families on legal protections such as the Genetic Information Nondiscrimination Act (GINA) to protect genetic information privacy.\n   - Ensure compliance with data security standards to protect genetic data.\n\n## Long-Term Management\n1. **Regular Monitoring**:\n   - Continuous monitoring of cardiac, renal, metabolic, auditory, and visual health is vital for early detection and management.\n   - Lifelong monitoring to optimize outcomes and improve quality of life.\n\n2. **Prognosis and Outcome Optimization**:\n   - Early intervention, targeted symptom management, and continuous support improve overall quality of life and outcomes.\n   \n3. **Supportive Therapies**:\n   - Emphasize educational, physical, and occupational therapies to enhance developmental outcomes.\n\nBy maintaining open communication and updating care plans with new research and treatment options, clinicians and families can ensure optimal care for individuals with Alström Syndrome.', 'execution_id': '4839', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.3,4o-4o
W-1,Wikipedia Fallback,What are the main symptoms of Marfan Syndrome?,"Must correctly list typical Marfan features per Wikipedia: tall stature/long limbs (dolichostenomelia), arachnodactyly, pectus deformity, scoliosis, ectopia lentis or myopia, aortic root dilation risking dissection. Should not invent dummy information.","{'output': 'I was unable to retrieve specific information on the symptoms of Marfan Syndrome from the internal educational materials or other priority sources. However, with your context, I can guide you based on my previous knowledge.\n\n**Marfan Syndrome Symptoms**\n\nMarfan Syndrome is a genetic disorder that affects the body’s connective tissue. Here are some common symptoms associated with Marfan Syndrome:\n\n- **Skeletal Changes**: Individuals often have long arms, legs, and fingers. They may also present with a tall and thin body type, scoliosis (curvature of the spine), and flat feet.\n\n- **Joint and Skin Issues**: Joints may be loose and flexible, leading to joint pain. The skin might be unusually stretchy.\n\n- **Eye Concerns**: Many patients experience lens dislocation (ectopia lentis), increased risk for myopia, and in some cases, a potential for retinal detachment.\n\n- **Cardiovascular Complications**: One of the most serious concerns is the risk of aortic dilation or aneurysm, as well as mitral valve prolapse, which can lead to significant cardiovascular complications.\n\nThese symptoms can vary widely among individuals affected by Marfan Syndrome, and early diagnosis and management are important to improve outcomes.\n\nIf you have other concerns or need further clarification, do let me know.', 'execution_id': '4840', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
W-2,Wikipedia Fallback,How is Cystic Fibrosis treated?,"Should mention airway clearance techniques, inhaled hypertonic saline or Dornase alfa, pancreatic enzyme replacement, CFTR modulators (ivacaftor, elexacaftor/tezacaftor/ivacaftor), antibiotics for infections, lung transplantation for end-stage disease; consistent with Wikipedia.","{'output': 'Here is an overview of the treatment options for Cystic Fibrosis (CF):\n\n### Overview of Cystic Fibrosis\n- CF is a genetic disorder affecting mainly the lungs and digestive system, leading to the production of thick, sticky mucus.\n\n### Treatment Options for Cystic Fibrosis\n\n1. **Medications**\n   - **Antibiotics:** These are used to treat and manage lung infections and can be administered orally, inhaled, or intravenously.\n   - **Inhaled Hypertonic Saline:** Helps in thinning the mucus, making it easier to expel.\n   - **Bronchodilators (e.g., Salbutamol):** Used to open the airways and make breathing easier.\n\n2. **Pancreatic Enzyme Replacement**\n   - Essential for digestion and absorption of nutrients, particularly for children.\n\n3. **Vitamin Supplements**\n   - Fat-soluble vitamins (A, D, E, and K) are often supplemented due to malabsorption issues.\n\n4. **Airway Clearance Techniques**\n   - Techniques such as chest physiotherapy are used to help clear mucus from the lungs.\n\n5. **Lung Transplantation**\n   - May be considered if lung function continues to decline severely.\n\n6. **Nutritional Support**\n   - High-calorie, high-protein diets are recommended to help maintain adequate weight and nutrition.\n\n### Considerations\n- **Regular Monitoring:** Frequent check-ups with healthcare providers for managing symptoms and complications.\n- **Life Expectancy:** Currently, the average life expectancy for those with CF ranges from 42 to 50 years in developed countries.\n\nCystic fibrosis requires a comprehensive, multidisciplinary management approach involving medication, physical therapies, nutritional support, and sometimes surgical interventions. Always consult healthcare providers for personalized treatment plans.\n\nIf you have more questions or need further information, feel free to ask!', 'execution_id': '4841', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,4o-4o
W-3,Wikipedia Fallback,What genetic changes cause Tay-Sachs Disease?,"Must state: bi-allelic pathogenic variants in the HEXA gene on chromosome 15 leading to β-hexosaminidase A deficiency; classic infantile, juvenile, adult forms associated with different residual enzyme activities; carrier frequency high in certain populations. No dummy data.","{'output': '### Overview of Tay-Sachs Disease\n\nTay-Sachs Disease is a genetic disorder caused by specific changes in the HEXA gene.\n\n### Genetic Changes\n\n- **HEXA Gene Mutations**: The condition is caused by mutations in the HEXA gene.\n  - **Function of HEXA**: This gene provides instructions for making part of an enzyme known as beta-hexosaminidase A.\n  - **Role of the Enzyme**: Beta-hexosaminidase A is crucial for the functioning of lysosomes—cell structures responsible for breaking down toxic substances and recycling cellular components.\n\n### Consequences of Genetic Mutations\n\n- **Enzyme Deficiency**: Mutations in the HEXA gene result in a deficiency of the beta-hexosaminidase A enzyme.\n- **Accumulation of GM2 Ganglioside**: This enzymatic deficiency leads to the buildup of a fatty substance called GM2 ganglioside in neurons.\n- **Neurological Symptoms**: The accumulation of GM2 ganglioside is directly responsible for the neurological symptoms seen in Tay-Sachs Disease.\n\nIf you need further information or clarification, feel free to ask!', 'execution_id': '4842', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
W-4,Wikipedia Fallback,What is the inheritance pattern of Hemophilia?,"Correct answer: X-linked recessive; Hemophilia A (F8) and B (F9); affected males, carrier females; 50 % chance of passing mutated allele to sons/daughters as per Wikipedia.","{'output': '**Inheritance Pattern of Hemophilia**\n\n- **X-linked Recessive Pattern**: Hemophilia is inherited in an X-linked recessive manner.\n  - **Affected Males**: Males have one X and one Y chromosome. If they inherit the affected X chromosome, they will exhibit the disorder due to the absence of a second X chromosome to offset the defect.\n  - **Carrier Females**: Females have two X chromosomes. If they inherit one affected X chromosome, they typically become carriers. They usually do not exhibit symptoms because their second X chromosome has a normal copy of the gene which compensates for the defective one.\n\nIf you have any further questions or need clarification, feel free to ask!', 'execution_id': '4843', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
W-5,Wikipedia Fallback,How is Alzheimer's Disease diagnosed?,"Should reference clinical criteria (progressive memory impairment affecting activities), supportive biomarkers (CSF Aβ42/tau, amyloid PET), MRI showing medial-temporal atrophy; exclude other dementias; info aligned with Wikipedia.","{'output': ""### Overview of Alzheimer's Disease Diagnosis\n\nAlzheimer’s disease (AD) is diagnosed through a comprehensive approach that typically involves:\n\n1. **Clinical Evaluation:**\n   - Medical History: Collecting information on health history, including any cognitive and behavioral changes observed by the patient or family.\n   - Neuropsychological Tests: Assessing memory, problem-solving, attention, counting, and language skills to evaluate cognitive functions.\n\n2. **Neurological Examination:**\n   - Physical tests to evaluate the nervous system’s function and check movement, senses, balance, and reflexes.\n\n3. **Imaging Tests:**\n   - MRI (Magnetic Resonance Imaging) or CT (Computed Tomography) scans to rule out other conditions and observe brain changes such as atrophy.\n   - PET (Positron Emission Tomography) scans may be used to assess the level of amyloid plaques, a hallmark of Alzheimer’s.\n\n4. **Laboratory Tests:**\n   - Blood tests to rule out other causes of memory impairment and dementia symptoms, such as thyroid disorders or vitamin deficiencies.\n\n5. **Biomarker Tests:**\n   - Tests for biomarkers in cerebrospinal fluid (CSF) and blood may be done to detect the presence of brain changes associated with Alzheimer’s.\n\n### Inheritance Patterns\n\n- **Familial Alzheimer's Disease (FAD):** In some cases, particularly early-onset forms, Alzheimer’s is caused by inherited genetic mutations. It is usually passed down in an autosomal dominant manner.\n\n### Ethical and Privacy Considerations\n\n- **Genetic Testing:** Deciding to undergo genetic testing for Alzheimer's predisposition can involve ethical and privacy concerns. Patients should be informed about the implications of discovering genetic risks, which may affect insurability and employability.\n\n### Management Options\n\n- **Currently No Cure:** Alzheimer’s disease does not have a cure. Treatment focuses on managing symptoms and improving quality of life.\n- **Medications:** Cholinesterase inhibitors and memantine are common drugs used to treat cognitive symptoms.\n- **Lifestyle Changes:** Cognitive training, exercise, and a healthy diet can support overall well-being.\n\nFeel free to ask if you have more questions or need further information!"", 'execution_id': '4844', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
W-6,Wikipedia Fallback,Describe the clinical management of Duchenne Muscular Dystrophy.,"Must cite corticosteroids to slow progression, cardiac surveillance and ACE-inhibitors, ventilatory support incl. nocturnal BiPAP, physiotherapy/orthotics, exon-skipping or gene therapies in development, wheelchair transition planning—per Wikipedia.","{'output': '### Clinical Management of Duchenne Muscular Dystrophy\n\nThe clinical management of Duchenne Muscular Dystrophy (DMD) involves a comprehensive and multidisciplinary approach. Here are the key aspects of managing DMD:\n\n1. **Metabolic Support**\n   - Dietary modifications and metabolic support supplements are employed to optimize cellular energy production.\n\n2. **Neurological Care**\n   - Regular monitoring and supportive interventions are necessary to manage cognitive fluctuations and transient sensory disturbances.\n\n3. **Genetic Counseling**\n   - Guidance is provided regarding inheritance patterns, recurrence risks, and assisting families with informed decision-making for future planning.\n\n4. **Supportive Therapies** \n   - Early educational interventions are crucial.\n   - Physical and occupational therapies are implemented to maximize developmental outcomes and overall quality of life.\n\n5. **Informed Consent**\n   - It is essential to ensure that patients and their families are fully informed about the scope, benefits, and limitations of genetic testing.\n\n6. **Long-Term Monitoring**\n   - Lifelong follow-up is recommended to adjust therapeutic strategies as necessary and to monitor cognitive and metabolic parameters.\n\n7. **Data Security and Genetic Nondiscrimination**\n   - Compliance with privacy regulations is maintained, and patients are informed about their rights and protections against misuse of genetic data.\n\nThese strategies aim to stabilize symptoms and improve the overall quality of life for patients with DMD.\n\nIf you have further questions or need more personalized guidance, feel free to ask!', 'execution_id': '4845', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.3,4o-4o
W-7,Wikipedia Fallback,What are the genetic risk factors for Down Syndrome?,"Answer: trisomy 21 (95 %), Robertsonian translocation involving chromosome 21 (~4 %), mosaic Down syndrome (~1 %); maternal age as main risk factor; consistent with Wikipedia.","{'output': '### Overview of Down Syndrome and Genetic Risk Factors\n\nDown syndrome is a genetic condition caused by an extra copy of chromosome 21, also known as trisomy 21. This additional genetic material alters the course of development and causes the characteristics associated with Down syndrome.\n\n#### Primary Genetic Causes:\n1. **Trisomy 21**: This results in three copies of chromosome 21 instead of the usual two. It accounts for about 95% of Down syndrome cases.\n2. **Mosaicism**: A condition where some cells in the body have the usual two copies of chromosome 21, and some have three. This is less common and results in a milder form of the syndrome.\n3. **Translocation**: Happens when part of chromosome 21 becomes attached to another chromosome, which can also lead to Down syndrome.\n\n#### Risk Factors:\n- **Advanced Maternal Age**: The risk of having a baby with Down syndrome increases with the mother’s age. Women over 35 are at a higher risk.\n- **Nondisjunction**: This is a random error during cell division in a parent’s reproductive cells, leading to an egg or sperm with an abnormal number of chromosomes.\n\n### Conclusions\nDown syndrome primarily arises from random genetic events, with maternal age being the most significant risk factor linked directly to the likelihood of nondisjunction. \n\nIf you have specific questions about the risk in particular familial situations, considering genetic counseling could be beneficial. They can provide tailored risk assessments and guidance for potential future pregnancies.\n\nIs there anything else you would like to know about Down syndrome or genetic conditions?', 'execution_id': '4846', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
W-8,Wikipedia Fallback,What is Rett Syndrome and how is it managed?,"Must state MECP2 pathogenic variants on X chromosome; affects girls after 6-18 months; regression of speech/purposeful hand use, stereotypic hand-wringing, seizures; management supportive—physical therapy, anti-epileptics, scoliosis surgery, feeding support. Use Wikipedia facts only.","{'output': '### Overview of Rett Syndrome\n\nRett Syndrome is a rare genetic neurological and developmental disorder that primarily affects females. It is caused by mutations in the MECP2 gene located on the X chromosome. The condition exhibits:\n- Normal early growth and development followed by a slowing of development.\n- Loss of purposeful hand use and the development of repetitive hand movements such as wringing.\n- Regression in speech.\n- Challenges with mobility and walking.\n\n### Management Options\n\nManagement of Rett Syndrome focuses on supportive care, as there is no cure. It often involves a multidisciplinary approach to address the multiple symptoms associated with the syndrome:\n\n1. **Physical Therapy**:\n   - Aims to improve mobility, balance, and coordination.\n\n2. **Occupational Therapy**:\n   - Focuses on daily living activities and enhancing hand use.\n\n3. **Speech Therapy**:\n   - Addresses communication difficulties, supporting nonverbal communication techniques since speech may be lost.\n\n4. **Medications**:\n   - Used to control symptoms like seizures, muscle stiffness, and possibly breathing irregularities.\n\n5. **Nutritional Support**:\n   - Ensures adequate nutrition, addresses feeding difficulties, and manages any gastrointestinal issues.\n\n6. **Regular Monitoring**:\n   - Regular health check-ups are crucial to monitor potential complications such as scoliosis, heart problems, and gastrointestinal issues.\n\n### Important Considerations\n\nGiven the complexity of Rett Syndrome, creating a personalized care plan is essential. Such plans should be developed by healthcare providers with proven experience in handling the condition, ensuring that all aspects of the syndrome are thoroughly managed to enhance the quality of life for the individual.\n\nIf you have more questions or need further details regarding Rett Syndrome, please feel free to ask.', 'execution_id': '4847', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
W-9,Wikipedia Fallback,How do you diagnose Wilson Disease?,"Correct response: low ceruloplasmin, high 24-h urinary copper, Kayser–Fleischer rings, ATP7B genetic testing, hepatic copper quantification on biopsy; per Wikipedia.","{'output': '### Diagnosing Wilson Disease\n\nWilson Disease is typically diagnosed through a combination of clinical evaluation and laboratory tests. Here are the main approaches:\n\n#### Clinical Evaluation\n- **Symptoms**: Consider symptoms such as liver disease, neurological or psychiatric issues, and presence of Kayser-Fleischer rings in the eyes.\n\n#### Laboratory Tests\n- **Blood Tests**: Measure serum ceruloplasmin levels, which are usually low in Wilson Disease.\n- **Copper Tests**: \n  - Serum copper levels may be low.\n  - 24-hour urinary copper excretion is usually elevated.\n- **Liver Function Tests**: Assess the extent of liver damage, if present.\n\n#### Liver Biopsy\n- **Hepatic Copper Content**: A liver biopsy to directly measure hepatic copper content can provide a definitive diagnosis, especially when other tests are inconclusive.\n\n#### Genetic Testing\n- **ATP7B Gene**: Genetic testing can identify mutations in the ATP7B gene, which is responsible for Wilson Disease.\n\nIf you have specific symptoms or concerns related to Wilson Disease or need further clarification, feel free to ask!', 'execution_id': '4848', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
W-10,Wikipedia Fallback,What are common symptoms of Noonan Syndrome?,"Should list short stature, webbed neck, ptosis/hypertelorism, congenital heart defects (pulmonary valve stenosis), pectus excavatum, coagulation defects, learning difficulties—as described on Wikipedia.","{'output': '**Common Symptoms of Noonan Syndrome**\n\nNoonan Syndrome is a genetic disorder that can manifest with a variety of symptoms, which may vary in severity among individuals. Here are some common features:\n\n- **Distinctive Facial Features**: \n  - Wide-set eyes\n  - Low-set ears\n  - A webbed neck\n\n- **Physical Characteristics**:\n  - Short stature\n\n- **Heart Issues**:\n  - Congenital heart defects, especially pulmonary valve stenosis\n\n- **Developmental Concerns**:\n  - Developmental delays\n\n- **Skeletal Abnormalities**:\n  - Differences in bone structure that can vary\n\n- **Other Possible Symptoms**:\n  - Bleeding disorders\n  - Eye problems\n\nSince the presentation of symptoms can differ greatly, a proper medical assessment is crucial for diagnosis and management.\n\nIf you have further questions or need more details, feel free to ask!', 'execution_id': '4849', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,4o-4o
N-1,Missing Information Handling,What are the key features of Phantom Syndrome?,Must state no reliable information found in any source and refuse to fabricate clinical details.,"{'output': 'I\'m sorry, but it seems there is no available information from our primary resources on ""Phantom Syndrome."" This condition might not be well-documented in the verified databases we have access to.\n\nIf you have any specific details or symptoms related to this syndrome, please share them with me. I can then try to provide more tailored information or explore other ways to assist you.', 'execution_id': '4850', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-2,Missing Information Handling,Explain the diagnosis of Mirage Disorder X.,"Answer should state no data available in protocol, GeneReviews, or Wikipedia; must not invent diagnostic criteria.","{'output': 'I\'m sorry, but I couldn\'t find any information on a disorder named ""Mirage Disorder X"" in the resources available to me. It\'s possible that this might be a rare or newly identified condition that is not widely documented yet. For the most accurate information, I recommend consulting with a healthcare professional or referring to specialized medical literature. If you have any other questions or concerns, feel free to let me know.', 'execution_id': '4851', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-3,Missing Information Handling,How is Nebula Disorder inherited?,Should acknowledge lack of information and avoid speculation about inheritance pattern.,"{'output': 'Unfortunately, I couldn\'t find specific information on the inheritance pattern of ""Nebula Disorder"" from the available databases. It\'s possible that ""Nebula Disorder"" may not be a recognized condition in the genetic literature available to me. If you have additional information or context about this disorder, I recommend consulting a healthcare professional or a genetic counselor. They may be able to provide insights based on recent studies or more specific genetic databases.\n\nIf you have any other questions or need assistance with a different topic, feel free to let me know!', 'execution_id': '4852', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-4,Missing Information Handling,What are the treatment options for Stellar Syndrome?,Must respond that no authoritative information exists and therefore treatments cannot be advised.,"{'output': 'I couldn\'t find any information on ""Stellar Syndrome"" from the reliable sources available. It\'s possible that the term may not refer to a recognized medical condition or might be known by another name. If you could provide more context or check the spelling, I may be able to assist further. Please let me know how else I might assist you!', 'execution_id': '4853', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-5,Missing Information Handling,Describe the clinical presentation of Twilight Syndrome.,Must report no available data; should not fabricate symptoms.,"{'output': ""I'm sorry, but I couldn't find any information regarding the clinical presentation of Twilight Syndrome from our verified resources. This condition may not be well-documented or recognized in standard medical references. If Twilight Syndrome is a real medical condition, you might want to consult a healthcare professional or another trusted medical resource for more detailed information.\n\nIf you have any other questions or concerns, feel free to ask!"", 'execution_id': '4854', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-6,Missing Information Handling,What is the molecular basis of Eosphorus Disorder?,Should state no molecular data found; do not fabricate gene names.,"{'output': ""I'm sorry, but there is no available information from our current resources regarding the molecular basis of Eosphorus Disorder.\n\nIf you have further questions or need additional assistance, feel free to ask."", 'execution_id': '4855', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-7,Missing Information Handling,List the symptoms of Arcadia Syndrome.,Must refuse to invent symptoms and clearly state no information exists.,"{'output': 'I wasn\'t able to find any specific information about a condition called ""Arcadia Syndrome"" in the sources available to me. This might mean that it is not a well-documented condition in medical literature, potentially has another name, or it might be extremely rare. I recommend checking with a healthcare professional or verifying the spelling and details of the condition you are asking about. If you have any further questions, feel free to ask.', 'execution_id': '4856', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-8,Missing Information Handling,What are the genetic markers for Lumenopathy?,Answer must say genetic markers unknown or not documented in any reputable source.,"{'output': 'I\'m unable to find any information regarding the genetic markers for Lumenopathy from the current resources. It\'s possible that ""Lumenopathy"" might not be a recognized genetic condition, or it might be referred to under a different name in available literature. \n\nIf you have additional details or context about this condition, please share them, and I\'ll do my best to assist you further. Alternatively, you might consider consulting with a healthcare professional or genetic counselor for more personalized advice.\n\nIf there\'s anything else you wish to know or explore further, feel free to ask.', 'execution_id': '4857', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-9,Missing Information Handling,How do you manage Monoculus Syndrome?,Must respond that management guidelines are nonexistent due to lack of information.,"{'output': ""I'm sorry, but there seems to be no specific information available in our current references regarding the management of Monoculus Syndrome. It might be a very rare or newly recognized condition, or possibly referred to by a different name in the medical literature. \n\nIf you could provide specific symptoms or more context about the condition, it might help me offer more targeted information. Alternatively, consulting with a medical professional or genetic counselor would be beneficial for managing rare genetic disorders. \n\nPlease let me know if there's anything else I can assist you with."", 'execution_id': '4858', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
N-10,Missing Information Handling,Explain the inheritance of Prismatic Disorder.,Should acknowledge no data on inheritance and avoid guessing.,"{'output': 'I couldn\'t find information on a condition called ""Prismatic Disorder"" from the sources I have access to. It appears that this might be a fictional or extremely rare and undocumented condition. If you have more information or if it might go by a different name, please let me know so I can assist further. For additional insights, consulting a medical professional or geneticist would be advisable.', 'execution_id': '4859', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
R-1,Referrals to Other Agents,Can you help me schedule a follow-up appointment for my child?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent' (or ends with <SCHEDULING>).,"{'output': ""I'll forward your request to the scheduling agent who can assist you with booking a follow-up appointment for your child. Thank you for reaching out, and they'll be in touch shortly to help."", 'execution_id': '4860', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
R-2,Referrals to Other Agents,How do I update my insurance information?,Pass if the agent routes to administrative and outputs to_agent: 'administrative_agent' (or ends with <ADMIN>).,"{'output': 'Your question has been forwarded to the administrative agent who can assist you with updating your insurance information.', 'execution_id': '4861', 'to_agent': 'administrative_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
R-3,Referrals to Other Agents,I want to know the clinic’s opening hours.,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent' (or ends with <FRONT_DESK>).,"{'output': ""I will forward your inquiry about the clinic's opening hours to the front-desk agent for assistance."", 'execution_id': '4862', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
R-4,Referrals to Other Agents,Can you connect me with a genetic counselor for a family planning session?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent'.,"{'output': ""I'll forward your request to the scheduling agent who can assist you with booking a session with a genetic counselor. Please hold on for a moment."", 'execution_id': '4863', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
R-5,Referrals to Other Agents,How do I get a copy of my lab results?,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent' or ends with <FRONT_DESK>.,"{'output': 'Please hold on while I forward your request to the front desk agent, who can assist you with obtaining a copy of your lab results.', 'execution_id': '4864', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
R-6,Referrals to Other Agents,Can I reschedule my appointment?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent'.,"{'output': 'Your request to reschedule an appointment will be forwarded to the scheduling agent for further assistance.', 'execution_id': '4865', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
R-7,Referrals to Other Agents,Who should I contact to change my address in the system?,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent' or ends with <FRONT_DESK>.,"{'output': 'Please contact the administrative agent to change your address in the system.', 'execution_id': '4866', 'to_agent': 'administrative_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,4o-4o
R-8,Referrals to Other Agents,What insurance plans does this clinic accept?,Pass if the agent routes to administrative and outputs to_agent: 'administrative_agent'.,"{'output': 'What insurance plans does this clinic accept?', 'execution_id': '4867', 'to_agent': 'administrative_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,4o-4o
R-9,Referrals to Other Agents,I need directions to the clinic.,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent'.,"{'output': ""I'll forward your message to the front-desk agent who can help with directions."", 'execution_id': '4868', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
R-10,Referrals to Other Agents,How do I cancel my appointment?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent'.,"{'output': 'I will forward your request to the scheduling agent, and they will assist you with canceling your appointment.', 'execution_id': '4869', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,4o-4o
T1-1,Tier 1 Retrieval,What are the symptoms and causes of Casio Syndrome?,"Must state that Casio Syndrome presents with (1) mild neurodevelopmental or motor-planning delays, (2) distinctive facial dysmorphism such as a broad nasal bridge and subtle ptosis, and (3) minor skeletal anomalies including clinodactyly or joint hyper-mobility. Must explain that the disorder is usually autosomal-recessive (with occasional autosomal-dominant reduced-penetrance families) caused by pathogenic variants in the candidate gene CASIO1. Should not mention any real disorders or external references (e.g., Noonan, Cornelia de Lange, etc.).","{'output': 'Overview of the Condition  \nCasio Syndrome is a genetic disorder known for its variable severity across individuals. Below is a summary of its key symptoms and causes.\n\nSymptoms  \n• Mild neurodevelopmental delays (slight delays in motor or cognitive development).  \n• Distinct facial features, such as a broad nasal bridge and mild drooping of the eyelids (ptosis).  \n• Minor skeletal anomalies, which can include curved fingers (clinodactyly) or hyperflexible joints.\n\nCauses  \n• Primarily inherited in an autosomal recessive manner, although some cases suggest an autosomal dominant pattern with reduced penetrance.  \n• Associated with mutations in genes involved in neurodevelopment and skeletal formation (such as the CASIO1 gene).  \n\nIf you have additional questions or would like more information on genetic testing and management, please let me know.', 'execution_id': '4872', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T1-2,Tier 1 Retrieval,Describe the diagnostic process for AADC Syndrome.,"Ideal answer lists: (1) clinical suspicion based on sub-dermal calcium deposits, dermal stiffening, painful nodules, intermittent skin lesions; (2) confirmatory skin biopsy demonstrating abnormal calcium deposition; (3) targeted molecular panel including CALD1 and related calcium-binding–protein genes; (4) whole-genome or whole-exome sequencing when panels are negative; (5) optional chromosomal microarray to detect pathogenic CNVs. Must explicitly avoid real aromatically-L-amino-acid decarboxylase deficiency or dopamine pathway discussion.","{'output': 'Overview of the Diagnostic Process for AADC Syndrome\n\n1. Clinical Evaluation  \n   • Initial diagnosis often begins with close observation of clinical symptoms such as developmental delays, abnormal movements (including oculogyric crises), and signs of impaired neurotransmitter function.  \n\n2. Neurotransmitter Metabolite Analysis  \n   • Measurement of neurotransmitter metabolites in the cerebrospinal fluid (CSF) is a key step in confirming deficiencies. Clinicians look for low levels of dopamine and serotonin metabolites, which can point toward an issue with the aromatic L-amino acid decarboxylase enzyme.  \n\n3. Genetic Testing  \n   • Genetic testing is performed to identify mutations in the DDC gene, which encodes the enzyme responsible for dopamine and serotonin production. A positive finding confirms the diagnosis of AADC deficiency.  \n\nIf you have any more questions or would like additional information, please let me know!', 'execution_id': '4873', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
T1-3,Tier 1 Retrieval,List the clinical features of Sickle Cell Disease – Sensory Coordination Deficiency.,"Should enumerate: impaired sensory integration, fine-motor and gross-motor coordination difficulties, spatial-awareness problems, balance issues similar to dyspraxia, and episodic sensory overload triggered by bright lights or loud noise. Must not reference hemoglobin, vaso-occlusion, anemia, or any real-world Sickle Cell Disease content.","{'output': 'Overview of the Condition  \nBelow is a list of potential clinical features associated with Sickle Cell Disease – Sensory Coordination Deficiency, based on our internal educational material:\n\n• Impaired sensory integration  \n• Motor coordination difficulties  \n• Struggles with fine motor skills  \n• Issues with spatial awareness and balance  \n• Symptoms similar to dyspraxia  \n• Difficulty with hand-eye coordination  \n• Delayed motor milestones  \n• Episodic sensory overload triggered by stimuli such as bright lights or loud noises  \n\nHope this information helps. Do you have any further questions or concerns about these features?', 'execution_id': '4874', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T1-4,Tier 1 Retrieval,What genetic testing is recommended for Casio Syndrome?,Answer must recommend: (1) a targeted panel covering CASIO1 and other neurodevelopmental/skeletal genes; (2) reflex next-generation sequencing—whole-exome or whole-genome—if targeted panel is uninformative; (3) chromosomal microarray to detect copy-number changes that could contribute; may note typical lab TAT of ~2–4 weeks. Must not recommend unrelated tests such as hemoglobin electrophoresis or FGFR3 sequencing.,"{'output': 'Below is an overview of the genetic testing approaches based on our internal material:\n\n• Targeted Gene Panels: These typically focus on candidate genes such as CASIO1, which has been implicated in both neurodevelopment and skeletal formation in individuals with Casio Syndrome.  \n• Next-Generation Sequencing (NGS): If targeted panels are inconclusive, healthcare providers may recommend whole-exome sequencing to look for novel or less common mutations.  \n• Chromosomal Microarray: This enables detection of copy number variations (CNVs) that could be relevant in the overall clinical presentation of Casio Syndrome.\n\nIf you have further questions about testing or would like additional clarification, please let me know.', 'execution_id': '4875', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T1-5,Tier 1 Retrieval,How is AADC Syndrome typically managed?,"Should describe a multi-disciplinary plan: dermatology and rheumatology for wound management/soft-tissue care; calcium-regulating drug therapy to limit dermal calcification; physical therapy to preserve flexibility; genetic counseling for recurrence risk; regular vascular evaluations if stiffness progresses. Must not mention neurotransmitter replacement, levodopa, or any therapy used for real AADC deficiency.","{'output': 'Hello! Thank you for sharing your question. Unfortunately, our verified resources do not currently contain information regarding how Aromatic L-Amino Acid Decarboxylase (AADC) Syndrome is typically managed. \n\nWould you like to share more about your symptoms or concerns so we can better understand your situation? Please let me know if you have any additional details you’d like to discuss.', 'execution_id': '4876', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
T1-6,Tier 1 Retrieval,Summarize the prognosis of Sickle Cell Disease – Sensory Coordination Deficiency.,"Must say prognosis is generally mild-to-moderate: with early occupational/physical and sensory-integration therapy most individuals adapt and develop compensatory strategies; some may need lifelong environmental accommodations in high-stimulation settings. Must avoid any discussion of sickle crises, transfusions, or hemoglobinopathies.","{'output': 'Overview of the Condition  \nSickle Cell Disease – Sensory Coordination Deficiency is characterized by an interplay between the classic symptoms of sickle cell disease and additional challenges related to sensory processing or coordination. While not universally present in every patient with sickle cell disease, this deficiency can affect a person’s ability to integrate and respond to sensory information.\n\nPrognosis  \n• Early Intervention: With prompt and appropriate interventions (e.g., occupational therapy, physical therapy, and sensory integration programs), many individuals experience only mild to moderate effects on daily function.  \n• Adaptation and Coping Strategies: Over time, patients often learn various strategies—such as structured breaks, the use of assistive tools, and environment modifications—to compensate for sensory processing delays.  \n• Long-Term Accommodations: Some individuals may benefit from lifelong adjustments in environments with high levels of stimulation (e.g., busy workplaces, crowded schools) to minimize discomfort or confusion.  \n\nIf you have any more questions or concerns, feel free to let me know.', 'execution_id': '4877', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T1-7,Tier 1 Retrieval,Which findings help differentiate Casio Syndrome from similar disorders?,"Expected distinctions: broad nasal bridge, subtle eyelid ptosis, clinodactyly, joint hyper-mobility, variable expressivity of cognitive delay—all together form a recognizable pattern absent in Noonan or Williams syndromes; presence of CASIO1 variants or pathogenic CNVs supports diagnosis. Should not mention real syndromes beyond a brief differentiating statement.","{'output': 'Below is an overview of the key findings that can help distinguish Casio Syndrome from conditions that share overlapping features, such as Noonan syndrome or Cornelia de Lange syndrome.\n\nOverview of Casio Syndrome  \n• A rare genetic condition characterized by mild developmental delays, certain facial features, and skeletal changes.  \n• Often requires clinical evaluation and genetic testing to confirm the diagnosis.  \n\nDifferentiating Findings  \n1. Neurodevelopmental Delays  \n   • Typically mild cognitive or motor delays.  \n   • These delays may be less severe than those seen in other syndromes with similar physical features.  \n\n2. Facial Features  \n   • Broad nasal bridge and subtle ptosis (slight drooping of the upper eyelid).  \n   • These features, while sometimes subtle, can help distinguish Casio Syndrome from other syndromes that present with more pronounced facial differences.  \n\n3. Skeletal Anomalies  \n   • Clinodactyly (inward curving of the fingers) or joint hypermobility.  \n   • These findings, in combination with the facial features and developmental history, strengthen the case for Casio Syndrome when performing differential diagnoses.  \n\nBecause many genetic conditions present with overlapping symptoms, comprehensive medical evaluation—including genetic testing—is crucial to accurately identify the genetic changes associated with Casio Syndrome. Once confirmed, the focus shifts to early interventions and support tailored to the individual’s developmental and medical needs.', 'execution_id': '4878', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T1-8,Tier 1 Retrieval,What are the main diagnostic clues for Sickle Cell Disease – Sensory Coordination Deficiency?,Must list: comprehensive neurodevelopmental examination with emphasis on balance tests and hand-eye coordination; sensory-response assessment to visual/auditory stimuli; genetic testing via a neuro-developmental gene panel including SENS1; optional functional MRI to show delayed sensory-integration activity. Must not mention hemoglobin testing or real SCD labs.,"{'output': 'Overview of Sickle Cell Disease – Sensory Coordination Deficiency (SCD – SCD)\n\n• Impaired Sensory Integration and Motor Coordination: Individuals often struggle with fine motor skills, spatial awareness, and balance, displaying symptoms that can resemble dyspraxia.  \n• Difficulty in Hand-Eye Coordination: This challenge can appear early in childhood development.  \n• Delayed Motor Milestones: Children may reach typical developmental motor milestones (such as crawling or walking) later than their peers.  \n• Episodic Sensory Overload: Sensitivity to bright lights, loud noises, or other strong stimuli can increase symptoms.  \n• Genetic Mutation in SENS1 Gene: This mutation affects centers in the brain responsible for integrating visual, auditory, and proprioceptive inputs.  \n\nDiagnostic Tools  \n• Clinical Evaluation: This involves neurodevelopmental assessments of coordination, balance, and sensory responsiveness.  \n• Genetic Testing: Specialized panels look for mutations in SENS1 and other sensory-regulating genes.  \n• Functional MRI (fMRI): Imaging can map neural activity in regions responsible for sensory processing, helping confirm the diagnosis.\n\nPlease let me know if you have any additional questions about these diagnostic clues or next steps.', 'execution_id': '4879', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
T1-9,Tier 1 Retrieval,Which clinical findings are seen in AADC Syndrome?,"Required findings: abnormal sub-epidermal calcium nodules, progressive dermal stiffening, painful skin lesions/nodules, and intermittent inflammatory plaques; early childhood onset; may mimic localized scleroderma. No reference to dopamine, movement disorder, or oculogyric crises.","{'output': 'I’m sorry, but I wasn’t able to find relevant information about Aromatic L-amino acid decarboxylase (AADC) deficiency in our available references.', 'execution_id': '4880', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
T1-10,Tier 1 Retrieval,How is AADC Syndrome inherited?,"Must state: autosomal-recessive inheritance with biallelic CALD1 pathogenic variants; 25 % recurrence risk for siblings; carrier parents typically asymptomatic; no mitochondrial, X-linked, or dominant inheritance details. Must avoid any mention of aromatic amino-acid decarboxylase pathways.","{'output': 'Overview of AADC Syndrome Inheritance\n\n• AADC syndrome (Aromatic L-amino acid decarboxylase deficiency) is inherited in an autosomal recessive manner. \n• This means that an individual must inherit two copies of the altered gene—one from each parent—in order to show signs and symptoms of the condition. \n• In most cases, each parent carries one copy of the altered gene but does not have the condition themselves (they are called “carriers”).\n\nI hope this clarifies your question about how AADC syndrome is passed down in families. If you have any more questions or concerns, feel free to let me know!', 'execution_id': '4881', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
T2-1,Tier 2 Retrieval,What is Huntington’s Disease according to the latest genetic insights?,"Should define the dummy disorder as a neurometabolic condition caused by autosomal-dominant missense or gain-of-function variants in HYPD1 leading to chronic dopamine over-production. Clinical presentation: uncontrolled hyperactivity, impulsive behavior, racing thoughts. Must clearly state that no CAG repeats, chorea, or classic Huntington's features are involved.","{'output': 'Overview of the Condition  \n• Huntington’s Disease (HD) is an autosomal dominant disorder, meaning that a mutation in only one copy of the responsible gene is sufficient to cause the condition.  \n• According to the retrieved information, HD involves a mutation in the HYPD1 gene, which leads to excessive dopamine production and results in a neurometabolic disorder.  \n• Each child of an affected individual has a 50% chance of inheriting the mutation.\n\nInheritance Patterns  \n• Since HD is inherited in an autosomal dominant manner, anyone who has the mutation will typically show signs of the condition at some point, and they can pass it on to their offspring with a 1 in 2 risk.  \n\nManagement Options  \n• While specific management strategies are not provided in the content we retrieved, individuals with HD commonly benefit from multidisciplinary care: including neurologic, genetic, and supportive therapy.  \n\nEthical and Privacy Considerations  \n• Because of the 50% inheritance risk, genetic counseling is strongly recommended for anyone with a family history of HD.  \n• Families may wish to consider genetic testing and counseling services before or during pregnancy, or when planning a family.  \n\nPlease let me know if you have any other questions or concerns.', 'execution_id': '4882', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.3,o1-4o
T2-2,Tier 2 Retrieval,How is Achondroplasia diagnosed in this context?,"Must describe: clinical suspicion when adults develop episodic cognitive fog, transient weakness, slurred speech triggered by posture change; work-up includes postural blood-pressure testing, cognitive and vascular elasticity assessments, transcranial Doppler ultrasound to measure cerebral blood-flow fluctuations; molecular confirmation by identifying recessive AC1 variants on a cerebro-vascular genetics panel. Must expressly avoid FGFR3 or skeletal-dysplasia references.","{'output': 'Hello! Achondroplasia is typically diagnosed through a combination of clinical assessment and genetic testing. Below is a brief overview based on available information:\n\n• Clinical Features: Diagnosis usually begins with recognition of characteristic signs such as short arms and legs (particularly the upper arms and thighs), a relatively average-sized torso, and a notably larger head with a prominent forehead (frontal bossing).\n\n• Imaging Studies: X-ray evaluations can reveal characteristic patterns of bone growth that suggest Achondroplasia.\n\n• Genetic Confirmation: Achondroplasia is caused by changes in the FGFR3 gene. Blood tests can be performed to confirm the presence of these changes, providing a definitive genetic diagnosis.\n\nDoes this address your question, or is there anything else you’d like to discuss?', 'execution_id': '4883', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
T2-3,Tier 2 Retrieval,What clinical features define Hulu Syndrome?,"Expected list: developmental delays, broad nasal bridge with epicanthal folds, congenital heart defects (commonly pulmonary stenosis), endocrine abnormalities (e.g., growth-hormone or thyroid imbalance). Mention high (but variable) penetrance and autosomal-dominant inheritance due to HULU1 mutations. Should not mention Williams or Noonan details.","{'output': 'Overview of Hulu Syndrome\nHulu Syndrome is characterized by several key medical findings that commonly present together. While the severity and combination of symptoms can vary from person to person, the major clinical features include:\n\n• Developmental Delays: These can affect both motor skills and cognitive function.  \n• Distinctive Facial Dysmorphism: Most common facial features are a broad nasal bridge and epicanthal folds (skin folds of the upper eyelid).  \n• Congenital Heart Defects: Pulmonary stenosis (a narrowing of the pulmonary valve) is frequently reported.  \n• Endocrine Abnormalities: Hormonal imbalances or other endocrine system concerns can occur, although the specific types can vary among individuals.\n\nIf you have more questions or would like additional details on diagnosis or management, feel free to let me know.', 'execution_id': '4884', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
T2-4,Tier 2 Retrieval,Describe the recommended management of Huntington’s Disease,"Must outline: dopamine-modulating medications (e.g., dopamine receptor partial antagonists) to reduce hyperactivity/impulsivity; structured behavioral therapy for impulse control; cognitive rehabilitation to improve executive function; regular psychiatric follow-up; genetic counseling for autosomal-dominant risk. Must not discuss tetrabenazine, chorea control, or neurodegeneration.","{'output': 'Overview of Huntington’s Disease Management\n\n1. Neurological & Psychiatric Support  \n• Dopamine-modulating medications may help manage behavioral and cognitive symptoms.  \n• Behavioral therapy can offer strategies for impulse control and emotional regulation.  \n• Cognitive rehabilitation supports executive functioning and focus.\n\n2. Prognosis and Monitoring  \n• Huntington’s disease symptoms vary widely, so regular follow-up with neurological professionals is crucial.  \n• Ongoing assessments allow healthcare providers to adjust treatments over time.\n\n3. Supportive Therapies  \n• Engage with a multidisciplinary team—occupational, physical, and speech therapy—to address movement, communication, and daily-task challenges.  \n• Tailored interventions help maintain quality of life.\n\n4. Genetic Counseling  \n• Essential for understanding inheritance patterns and discussing reproductive options.  \n• Helps patients and families plan for the future and cope with risk of transmission.\n\nI hope this helps clarify the recommended management strategies for Huntington’s disease. Is there anything more you would like to discuss?', 'execution_id': '4885', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T2-5,Tier 2 Retrieval,Which gene mutation is associated with Achondroplasia?,Correct answer: recessive loss-of-function variants in AC1 disrupting cerebral-artery elasticity and causing brief ischemic episodes. Must specify AC1—not FGFR3—and link to episodic cerebrovascular symptoms rather than skeletal dysplasia.,"{'output': 'Overview of the Condition  \n• Achondroplasia is a genetic condition characterized by dwarfism, particularly affecting bone growth in the arms and legs.\n\nAssociated Gene Mutation  \n• Achondroplasia is commonly caused by a mutation in the FGFR3 (fibroblast growth factor receptor 3) gene.\n\nInheritance Pattern  \n• It follows an autosomal dominant pattern; a single copy of the mutated gene is sufficient to cause the condition.\n\nIf you have any further questions or concerns, please let me know.', 'execution_id': '4886', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
T2-6,Tier 2 Retrieval,Explain the pathophysiology of Hulu Syndrome.,"Should state that HULU1 mutations impair a signaling pathway involved in cardiac morphogenesis and endocrine regulation, leading to combined congenital heart defects and hormonal dysregulation. Variable expressivity explained by gene dosage and potential modifier loci. Must not introduce real-world pathways or Ras/MAPK.","{'output': 'Overview of the Condition  \nHulu Syndrome is a rare genetic disorder characterized by:  \n• Developmental delays.  \n• Distinctive facial dysmorphism (e.g., broad nasal bridge, epicanthal folds).  \n• Congenital heart defects (commonly pulmonary stenosis).  \n• Endocrine abnormalities.  \n\nUnderlying Genetic Basis  \n• Autosomal dominant inheritance.  \n• High penetrance (individuals who inherit the mutation typically show symptoms).  \n• Mutations can be inherited or arise de novo (new mutations not present in parents).  \n\nPathophysiology  \n• Developmental and Structural Abnormalities: The gene variant(s) involved in Hulu Syndrome disrupt normal developmental processes, especially in tissues associated with craniofacial structures, the heart, and endocrine glands.  \n• Variable Expressivity: Even within the same family, certain organs or systems can be affected more severely in one individual than in another, pointing to variability in how the genetic change influences developmental pathways.  \n• Neurodevelopmental Impact: Genetic disruptions contribute to the delays in reaching developmental milestones, due to the altered processes guiding brain growth and function.  \n• Endocrine Dysfunction: The endocrine abnormalities may arise from impaired development of glands or disrupted regulation of hormone production, affecting metabolic balance.  \n• Cardiac Involvement: Pulmonary stenosis and other congenital heart defects occur when the gene variant interferes with the intricate processes shaping the heart’s structure during early embryonic growth.  \n\nManagement Implications  \nBecause Hulu Syndrome involves multiple systems, coordinated care among developmental specialists, cardiologists, and endocrinologists is central to its management.  \n\nHope this clarifies the pathophysiology of Hulu Syndrome. Please let me know if you have any further questions or concerns.', 'execution_id': '4887', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,o1-4o
T2-7,Tier 2 Retrieval,What is the inheritance pattern and genetic basis for Huntington’s Disease?,"Must state: autosomal-dominant inheritance; pathogenic HYPD1 variants cause excess dopamine synthesis/metabolism, resulting in hyperactive phenotype; penetrance approaches 100 % by late adolescence. Must not mention CAG repeat length or HTT gene.","{'output': 'Overview of the Condition  \n• According to the GeneReviews information we found, Huntington’s Disease is inherited in an autosomal dominant pattern. This means only one altered copy of the responsible gene is sufficient to cause the condition.  \n• GeneReviews mentions the gene as “HYPD1,” and indicates that dysfunction in this gene leads to excessive dopamine production.  \n\nInheritance Pattern  \n• Autosomal dominant: a child of an affected individual has a 50% chance of inheriting the altered gene and developing the condition.  \n\nGenetic Basis  \n• A single gene mutation in what GeneReviews refers to as HYPD1 underlies Huntington’s Disease.  \n• No additional references were provided in the materials we retrieved.\n\nNote: These details are drawn directly from the GeneReviews tool output. No further hospital-specific or additional genetic references are available in our system at this time.', 'execution_id': '4888', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
T2-8,Tier 2 Retrieval,How are cognitive symptoms managed in Achondroplasia ?,"Answer should include: blood-flow stabilizing medications to enhance cerebral perfusion; speech and cognitive therapy sessions to address transient speech difficulties and concentration lapses; lifestyle adjustments (avoid sudden posture changes, maintain hydration); periodic neurological monitoring. Must not reference growth hormone, orthopedics, or FGFR3.","{'output': 'Overview of Cognitive Symptom Management in Achondroplasia\n\nBased on information from GeneReviews® regarding cognitive symptom management in Achondroplasia, the following approaches may be utilized:\n\n1. Speech & Cognitive Therapy  \n   • Helps address intermittent speech difficulties and fluctuations in attention or memory.  \n   • Aims to improve communication skills and reinforce cognitive functioning.\n\n2. Blood Flow Stabilization Therapy  \n   • Medications may be prescribed to enhance cerebral perfusion.  \n   • Can help stabilize cognitive symptoms that stem from reduced blood flow to the brain.\n\n3. Lifestyle Adjustments  \n   • Avoiding sudden changes in posture and maintaining good hydration can contribute to vascular health.  \n   • These measures may help reduce episodes of “cognitive fog” or confusion.\n\n4. Ongoing Neurological Monitoring  \n   • Regular follow-up exams help detect any progression of potential cerebrovascular issues early.  \n   • Therapies and lifestyle strategies can be adjusted based on an individual’s response.\n\nPlease let me know if you have further questions or concerns about managing cognitive symptoms associated with Achondroplasia.', 'execution_id': '4889', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
T2-9,Tier 2 Retrieval,How is Hulu Syndrome diagnosed genetically?,"Must mention: targeted gene panel including HULU1, reflex NGS or whole-exome sequencing if panel negative, and microarray to detect CNVs; typical laboratory turnaround 2–3 weeks; recommendation for confirmatory testing of relatives. Must avoid references to real-world Noonan/Williams testing.","{'output': 'Overview of Genetic Diagnosis for Hulu Syndrome:\n\n• Initial Clinical Assessment: A detailed clinical evaluation identifies key features suggestive of Hulu Syndrome.  \n• Targeted Gene Panels: Specific panels that include the putative HULU1 gene (and other genes commonly linked to similar syndromes) can pinpoint known disease-causing variants.  \n• Next-Generation Sequencing (NGS): In cases where targeted panels are inconclusive, broader methods like whole-exome sequencing can identify novel or less common mutations related to Hulu Syndrome.  \n• Microarray Analysis: Used to detect large-scale changes such as copy number variations (CNVs) that might be associated with the disorder.\n\nThese tests aim to confirm Hulu Syndrome by identifying characteristic genetic mutations.  \n\nAre you satisfied with this answer, or do you have any further questions?', 'execution_id': '4890', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
T2-10,Tier 2 Retrieval,How is Achondroplasia inherited?,Correct statement: autosomal-recessive inheritance with biallelic AC1 variants; carrier parents asymptomatic; 25 % recurrence risk. Must not mention dominant FGFR3 or classic short-stature phenotype.,"{'output': 'Overview of Achondroplasia Inheritance\n\n• Achondroplasia follows an autosomal dominant pattern. This means that having just one copy of the changed gene (mutation) is enough to cause the condition.  \n• Although it can be passed down from an affected parent, most cases of achondroplasia result from a new (de novo) gene mutation in families with no previous history of the condition.\n\nDoes this address your concerns, or do you have any further questions?', 'execution_id': '4891', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
S-1,Multi-Source Synthesis,How is Aurora Syndrome managed across clinical and molecular perspectives?,"Expected synthesis: (1) clinical management—multidisciplinary team including neurology and dermatology; early speech/motor therapy; monitoring for visual hallucinations or brief seizures; supportive cognitive interventions; (2) molecular strategy—if seizures occur, anti-epileptic therapy; counseling on AUR1 mutation implications; recommendation for NGS/WES when initial panel negative; genetic counseling for autosomal-dominant inheritance. Should include both sets of details in a coherent answer.","{'output': 'Overview of Aurora Syndrome  \nAurora Syndrome is a rare genetic disorder characterized by:  \n• Episodic visual disturbances  \n• Distinctive pigmentary skin anomalies  \n• Mild cognitive delays  \n\nManagement typically involves a multidisciplinary approach encompassing both clinical (symptom-focused) and molecular (genetic) strategies.\n\nClinical Management  \n1. Early Diagnosis:  \n   - Because symptoms can be subtle or variable, prompt evaluation is key.  \n   - Comprehensive assessments of skin, neurological function, and developmental milestones help identify any delays or issues early.  \n\n2. Symptomatic Treatment:  \n   - Visual hallucinations, headaches, and mild cognitive impairments can be managed through a combination of medication, counseling, and individualized therapeutic interventions.  \n\n3. Developmental Support:  \n   - Speech, motor coordination, and cognitive therapy (e.g., speech therapy, physical/occupational therapy) can greatly assist in meeting developmental milestones.  \n\n4. Ongoing Monitoring:  \n   - Regular follow-up ensures adjustments in treatment as symptoms evolve and helps track disease progression.  \n\nMolecular Perspectives  \n1. Genetic Testing:  \n   - Targeted gene panels help identify the mutation(s) associated with Aurora Syndrome.  \n   - Inheritance can be autosomal dominant with variable expressivity or can occur de novo.  \n\n2. Genetic Counseling:  \n   - Important for family planning and to understand recurrence risks.  \n   - Discusses psychosocial challenges that may arise from a confirmed genetic diagnosis.  \n\nConclusion  \nCombining clinical management and molecular insights provides the most comprehensive care plan for Aurora Syndrome. This integrated approach helps ensure early intervention, appropriate therapies, and support for the individual and their family. \n\nI hope this information helps. Do you have any further questions or concerns?', 'execution_id': '4892', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
S-2,Multi-Source Synthesis,Summarize the genetic mutations and diagnostic steps for Roku Syndrome.,"Must merge: Tier-1 clinical scoring (episodic rigidity triggered by sound, dystonic facial movements, macular hypopigmentation, mild CK elevation, family history) with Tier-2 molecular data (heterozygous RKS1 c.1487G>A, p.Gly496Asp on 12q24.3; incomplete penetrance, especially in males < 18). Include advice to offer RKS1 sequencing to symptomatic and at-risk relatives. Should avoid mention of dystrophin or other real muscular-dystrophy genes.","{'output': 'Overview of Genetic Mutations  \n• Roku Syndrome is a rare condition inherited in an autosomal dominant manner.  \n• While genetic testing can confirm the diagnosis (especially in unclear cases), it is often not required for mild presentations.\n\nDiagnostic Steps  \n1. Clinical Evaluation  \n   • Look for episodic neuromuscular rigidity.  \n   • Check for facial asymmetry and pigmentary retinopathy.  \n   • Monitor for dystonic facial movements triggered by auditory stimuli.  \n   • Perform a fundoscopic examination to identify macular hypopigmentation.\n\n2. Lab Testing  \n   • Assess for mild-to-moderate elevations in serum creatine kinase (CK) levels.\n\n3. Genetic Testing (If Needed)  \n   • Confirmatory testing can be pursued if the clinical diagnosis is uncertain.  \n   • Genetic results can be helpful in atypical cases or when clarifying risk for family members.\n\nIf you have any further concerns or questions, please let me know!', 'execution_id': '4893', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.6,o1-4o
S-3,Multi-Source Synthesis,What is the pathophysiology and inheritance pattern of Aurora Syndrome?,"Should state: autosomal-dominant inheritance with variable expressivity; pathogenic mutations in AUR1 disrupt neural-crest migration and melanocyte function, explaining pigmentary skin changes and episodic visual disturbances; clinical phenotype includes Blaschko-line hypo/hyper-pigmentation and mild cognitive delay. Must integrate both molecular and clinical pieces.","{'output': 'Overview of Aurora Syndrome  \n• Aurora Syndrome is a rare genetic disorder characterized by distinct episodes of visual disturbances, pigmentary skin anomalies, and mild cognitive delays.  \n• Early identification and timely intervention are important due to variable and often subtle presentation.\n\nPathophysiology  \n• The precise pathophysiological mechanisms are not fully delineated, but the disorder is associated with episodic visual changes and skin pigmentation differences, indicating an underlying genetic influence on neurological and melanocytic pathways.  \n• Cognitive involvement is generally mild, suggesting partial or selective impact on neurological development.\n\nInheritance Pattern  \n• Aurora Syndrome follows an autosomal dominant inheritance pattern.  \n• It shows variable expressivity, meaning symptom severity and presentation can widely differ even within the same family.  \n• Both familial clustering and de novo (new) mutations have been documented.\n\nI hope this clarifies the pathophysiology and inheritance pattern of Aurora Syndrome. Do you have any additional questions or concerns?', 'execution_id': '4894', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
S-4,Multi-Source Synthesis,How is Alström Syndrome diagnosed and managed based on internal protocols and recent literature?,"Must combine: internal protocol—baseline eosinophil count > 500/mm³ (×2), CT angiography showing arterial wall thickening or dissections, early low-dose methotrexate & prednisone, vascular-surgery consult; plus literature—ELP5 dysregulation causes vascular tortuosity/rupture, IL-5 up-regulation, need for custom gene panel; environmental triggers (chlorinated hydrocarbons) may precipitate episodes. Genetic counseling recommended when familial clustering.","{'output': 'Below is a summary of the hospital’s internal approach (“Internal Protocol”) followed by notes from recent literature. There appears to be a discrepancy between the hospital’s rare disease manual and externally published resources regarding Alström Syndrome. Nonetheless, the hospital’s official protocol is detailed here first.\n\n────────────────────────────────────────\n1. Internal Protocol Overview (Hospital Manual)\n────────────────────────────────────────\n• Description: Classified as a “vascular connective tissue disorder,” Alström Syndrome in the internal manual is characterized by spontaneous arterial dissections, episodic claudication, and persistent eosinophilia, typically presenting in early adulthood.  \n• Diagnostic Criteria:  \n  1) Two consecutive eosinophil counts >500/mm³.  \n  2) CT angiography evidence of arterial wall thickening or luminal irregularities.  \n  3) Negative for FBN1 and COL3A1 mutations.  \n• Management:  \n  1) Early immunosuppression with low-dose methotrexate and prednisone.  \n  2) Vascular surgery consult for dissection management.  \n  3) Genetic counseling in recurrent familial cases.  \n\n────────────────────────────────────────\n2. Notes from Recent Literature\n────────────────────────────────────────\n• Some external references (such as GeneReviews) describe Alström Syndrome primarily as a multi-system disorder with cone-rod dystrophy (vision loss), hearing impairment, obesity, diabetes mellitus, and cardiomyopathy.  \n• Gene-level testing noted in other publications may involve variants in ELP5, though the internal manual does not include genetic details apart from excluding FBN1 and COL3A1.  \n\nDue to the discrepancy, it is important to follow our hospital’s official diagnostic/management guidelines unless further clarification is provided by your clinical team. If you have additional questions or concerns about genetic differences reported in other literature, please discuss with your physician or request a genetics consultation.\n\nDo you have any more questions or something else you would like to clarify?', 'execution_id': '4895', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,o1-4o
S-5,Multi-Source Synthesis,Describe the clinical and genetic features that distinguish Aurora Syndrome from other neurocutaneous disorders.,"Must cover: patchy hypo/hyper-pigmentation along Blaschko's lines, episodic visual hallucinations/disturbances, mild cognitive delay, occasional self-limited seizures; AUR1 mutation as genetic hallmark; autosomal-dominant pattern; differentiate from real disorders by absence of café-au-lait (NF1) or port-wine (Sturge-Weber).","{'output': 'Overview of the Condition  \nAurora Syndrome is a distinct neurocutaneous disorder that combines specific skin pigmentation changes with neurological symptoms and mild developmental issues. Though it shares certain features with other neurocutaneous syndromes, several clinical and genetic hallmarks help set it apart.\n\nClinical Features  \n• Dermatologic Findings: Characterized by patchy areas of hypo- and hyperpigmentation arranged in a pattern that often follows the lines of Blaschko.  \n• Neurological Features: Includes episodes of visual hallucinations or disturbances, mild cognitive impairment, occasional transient headaches, and rare brief seizure activity.  \n• Developmental Delays: Children may show slight delays in speech and motor coordination during early development.\n\nGenetic Features  \n• Inheritance Pattern: Typically follows an autosomal dominant pattern with variable expressivity. De novo mutations can also occur.  \n• Genetic Testing: Targeted gene panel testing can confirm the diagnosis by detecting the syndrome’s characteristic genetic changes.\n\nBy combining these unique dermatologic signs with the syndrome’s neurological and developmental presentation, Aurora Syndrome can usually be differentiated from other, more common neurocutaneous disorders.', 'execution_id': '4896', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
S-6,Multi-Source Synthesis,What molecular and clinical features distinguish Roku Syndrome from other disorders?,"Must list clinical triad—episodic neuromuscular rigidity, stimulus-induced dystonic facial asymmetry, pigmentary retinopathy with macular hypopigmentation—and link to RKS1 missense variant causing calcium-signaling defect; note incomplete penetrance and mitochondrial dysfunction on muscle biopsy in severe cases. Explain that these elements distinguish it from dystonia or retinitis pigmentosa of other etiologies.","{'output': 'Overview of Roku Syndrome  \nRoku Syndrome is distinguished by a specific combination of clinical manifestations and molecular markers that set it apart from other disorders.\n\nClinical Features:  \n• Episodic Neuromuscular Rigidity: Individuals experience episodes of muscle stiffness.  \n• Facial Asymmetry: Noticeable asymmetry in facial movements.  \n• Pigmentary Retinopathy: Characterized by a macular hypopigmentation on fundoscopic examination.  \n• Onset in Early Adolescence: Symptoms typically start between ages 10 and 14.  \n• Dystonic Facial Movements Triggered by Auditory Stimuli: Sudden facial muscle spasms can occur in response to sounds.\n\nDiagnostic Markers:  \n• Mild-to-Moderate Elevation in Serum Creatine Kinase (CK) Levels: Elevated CK levels are frequently found.\n\nInheritance Pattern:  \n• Autosomal Dominant: This genetic transmission pattern helps differentiate Roku Syndrome from some similar neuromuscular conditions.\n\nThese molecular and clinical features together distinguish Roku Syndrome from other disorders with overlapping symptoms.', 'execution_id': '4897', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
S-7,Multi-Source Synthesis,What are the diagnostic and management strategies for Alström Syndrome from both clinical and molecular perspectives?,Answer must mention: CT or MR angiography for mesenteric/renal artery dissections; persistent eosinophilia monitoring; early immunosuppression (low-dose methotrexate + prednisone); surgical repair for ruptures; molecular testing via custom panel including ELP5 because standard panels omit it; counsel on avoiding chlorinated-hydrocarbon exposure; offer family genetic counseling when recurrent.,"{'output': 'Overview of Alström Syndrome  \nAlström Syndrome is characterized by a multisystem involvement that may include inflammatory vasculopathy and other systemic manifestations. The following summarizes key points regarding diagnosis (both clinical and molecular) and management strategies, based on the content retrieved.\n\n────────────────────────────────────────\nCLINICAL DIAGNOSTIC STRATEGIES\n────────────────────────────────────────\n• Baseline Eosinophil Count  \n  - According to our references, a baseline eosinophil count greater than 500/mm³ on two separate occasions may be an important clinical clue.\n\n• Imaging Studies  \n  - CT angiography is used to look for arterial wall thickening or luminal irregularities, which can point to vascular involvement.\n\n• Differential Diagnosis  \n  - It is important to exclude conditions such as certain Ehlers-Danlos variants by ruling out FBN1 and COL3A1 mutations.\n\n────────────────────────────────────────\nMOLECULAR DIAGNOSTIC STRATEGIES\n────────────────────────────────────────\n• Genetic Testing  \n  - While genetic testing for Alström Syndrome was not emphasized in these references, they note that custom or specialized genetic testing may be warranted if there is a strong clinical suspicion.\n  - Emerging research suggests possible links to the ELP5 gene and environmental factors (e.g., exposure to chlorinated hydrocarbons), though this is not part of standard testing at this time.\n\n• Genetic Counseling  \n  - In familial or recurrent cases, genetic counseling can help families understand inheritance patterns, potential risks to offspring, and the implications of molecular testing.\n\n────────────────────────────────────────\nMANAGEMENT STRATEGIES\n────────────────────────────────────────\n• Immunosuppressive Therapy  \n  - Low-dose methotrexate and prednisone may be used to manage inflammation and reduce vascular complications.\n\n• Surgical/Interventional Care  \n  - When arterial dissection or significant vascular changes occur, a prompt vascular surgery consult is recommended.\n\n• Supportive Therapies  \n  - Early educational interventions, along with physical and occupational therapies, can aid in optimizing developmental outcomes and quality of life.\n\n• Environmental Considerations  \n  - Minimizing potential environmental triggers (such as certain chemicals) may be part of a broader, multidisciplinary approach.\n\n────────────────────────────────────────\nCONCLUSION & NEXT STEPS\n────────────────────────────────────────\nA thorough clinical assessment—supported by imaging, laboratory evaluations (like eosinophil counts), and selected molecular investigations—is central to diagnosing Alström Syndrome. Management often relies on immunosuppressive therapies, supportive care, and genetic counseling when indicated. Because this condition can affect multiple organ systems, a multidisciplinary team approach is encouraged to address the full spectrum of needs.\n\nI hope this overview clarifies the diagnostic and management strategies for Alström Syndrome. Is there anything else you would like to discuss or clarify regarding this condition?', 'execution_id': '4898', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
S-8,Multi-Source Synthesis,Compare the neurological findings and molecular mechanisms in Aurora Syndrome.,"Should state: neurological manifestations—episodic visual disturbances, mild cognitive delay, rare brief seizures—correlate with AUR1-mediated disruption of neural-crest migration and melanocyte differentiation; link pigmentary skin changes and white-matter MRI anomalies (subtle). Synthesize clinical and molecular views.","{'output': 'Overview of Aurora Syndrome\n\nBelow is a comparison of the key neurological findings and known molecular mechanisms related to Aurora Syndrome, based on available internal protocols.\n\n1. Neurological Findings  \n• Visual hallucinations or disturbances: Episodes may be brief and can manifest as visual distortions or illusions.  \n• Mild cognitive impairment: Some individuals experience subtle memory or attention difficulties.  \n• Occasional transient headaches: These headaches are typically short-lived and do not appear to have a consistent trigger.  \n• Rare brief, self-limited seizures: When seizures do occur, they tend to resolve quickly without long-term complications.  \n\n2. Molecular Mechanisms  \n• Autosomal dominant inheritance: The condition often appears in multiple generations within a family.  \n• Variable expressivity: Even within the same family, symptoms can differ considerably in severity and presentation.  \n• Familial clustering and de novo mutations: While familial patterns are common, some cases arise from new (de novo) mutations.  \n• Genetic testing: Targeted gene panels can help confirm the diagnosis by identifying the specific mutation(s), though detailed molecular pathways have not been fully characterized in the reviewed material.  \n\nSummary  \n• Neurologically, Aurora Syndrome can present with generally mild and subtle symptoms, including visual disturbances, transient headaches, mild cognitive issues, and rare seizures.  \n• Molecularly, it is primarily linked to an autosomal dominant pattern of inheritance, with variability even across affected family members. Although the exact molecular pathways are not completely defined in current references, testing can help identify causative mutations.\n\nI hope this helps clarify the differences and connections between the clinical and genetic aspects of Aurora Syndrome. If you have any more questions or concerns, please let me know.', 'execution_id': '4899', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.5,o1-4o
S-9,Multi-Source Synthesis,Summarize how family history and de novo mutation contribute to Roku Syndrome according to both clinical and genetic data.,"Must explain: autosomal-dominant pedigree often evident, but ~28 % cases arise from de novo RKS1 c.1487G>A variants; incomplete penetrance particularly in male carriers < 18 yrs; clinical scoring system uses family history + rigidity/retinal findings; recommend cascade screening. Should note mitochondrial dysfunction in strongly affected individuals.","{'output': 'Overview of Roku Syndrome  \n• Roku Syndrome is characterized as a rare autosomal dominant disorder.  \n• Autosomal dominant disorders often have a strong family history, as an affected parent can pass the condition to offspring with a 50% chance per pregnancy.\n\nFamily History Contribution  \n• In most cases, clinical findings emphasize the importance of family history.  \n• Because of its autosomal dominant inheritance, one side of the family often shows noticeable patterns of similar signs, symptoms, or confirmed diagnosis of Roku Syndrome.\n\nDe Novo Mutations  \n• Based on current internal educational materials, there is no specific mention of de novo (new) mutations playing a documented role in Roku Syndrome.  \n• The primary focus remains on autosomal dominant inheritance, suggesting that most cases arise from an inherited pathogenic variant rather than a new mutation in the individual.\n\nIf you have any further questions or concerns, I’m here to help. Are you satisfied with this explanation?', 'execution_id': '4900', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.4,o1-4o
S-10,Multi-Source Synthesis,"What are the recommended follow-up protocols for Alström Syndrome, including both clinical and genetic considerations?",Follow-up plan: lifelong vascular imaging (annual CT/MR angiography of mesenteric/renal vessels); eosinophil counts every 6 months; adjust immunosuppressive regimen per disease activity; repeat surgical consult for new dissections; genetic counseling for ELP5-positive families; environmental counseling to avoid chlorinated solvents; consider enrollment in vascular-gene therapy trials if available.,"{'output': 'Overview of the Condition  \nAlström Syndrome is a multisystem genetic disorder that can affect many organs, including the heart, endocrine system, vision, and hearing. Because of this multisystem involvement, a coordinated and proactive approach to care is essential.\n\nClinical Considerations  \n• Multidisciplinary Monitoring: A team approach that may include cardiologists, endocrinologists, ophthalmologists, audiologists, and developmental specialists.  \n• Regular Assessments:  \n  – Cardiac Health: Periodic echocardiograms and cardiology checkups.  \n  – Endocrine Function: Monitor blood sugar and thyroid function due to risk of diabetes and potential thyroid irregularities.  \n  – Vision and Hearing: Scheduled evaluations by eye and ear specialists to track progression of retinal degeneration and hearing loss.  \n  – Growth and Development: Continued tracking of growth milestones and overall development.\n\nGenetic Considerations  \n• Genetic Counseling:  \n  – Important for understanding the inheritance pattern.  \n  – Provides guidance for family planning and recurrence risks.  \n• Genetic Testing:  \n  – Could be updated as new technologies or insights develop, possibly including advanced sequencing techniques.  \n• Family Screening:  \n  – May be considered to identify at-risk relatives or carriers.  \n  – Facilitates early interventions and management where necessary.\n\nBy following these guidelines—combining regular, targeted clinical evaluations with appropriate genetic counseling and testing—individuals with Alström Syndrome can receive comprehensive support and management over time.', 'execution_id': '4901', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.0,o1-4o
W-1,Wikipedia Fallback,What are the main symptoms of Marfan Syndrome?,"Must correctly list typical Marfan features per Wikipedia: tall stature/long limbs (dolichostenomelia), arachnodactyly, pectus deformity, scoliosis, ectopia lentis or myopia, aortic root dilation risking dissection. Should not invent dummy information.","{'output': 'Overview of Marfan Syndrome  \nMarfan syndrome is a genetic condition affecting connective tissue, which supports various structures throughout the body. Because connective tissue is found in many areas—including the skeleton, eyes, heart, and other organs—Marfan syndrome often has multiple systems involved.\n\nKey Symptoms and Features  \n• Skeletal:  \n  – Tall stature and unusually long limbs.  \n  – Long, slender fingers and toes (arachnodactyly).  \n  – Flexible joints.  \n  – Curvature of the spine (scoliosis).  \n  – Chest deformities (e.g., a sunken or protruding chest).  \n\n• Cardiovascular:  \n  – Enlargement (dilation) of the aorta, which can progress to aortic dissection or rupture.  \n  – Mitral valve prolapse (heart valve dysfunction).  \n\n• Ocular:  \n  – Dislocation of the eye lens (ectopia lentis).  \n  – Nearsightedness (myopia).  \n  – Increased risk of retinal detachment.  \n\n• Other Features:  \n  – Stretch marks (striae) not related to weight changes.  \n  – Potential for lung complications such as pneumothorax (collapsed lung).  \n\nIf you suspect Marfan syndrome, an evaluation typically includes a physical examination, imaging of the heart (such as an echocardiogram), and assessment by an ophthalmologist. Genetic testing can also confirm the diagnosis.', 'execution_id': '4902', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
W-2,Wikipedia Fallback,How is Cystic Fibrosis treated?,"Should mention airway clearance techniques, inhaled hypertonic saline or Dornase alfa, pancreatic enzyme replacement, CFTR modulators (ivacaftor, elexacaftor/tezacaftor/ivacaftor), antibiotics for infections, lung transplantation for end-stage disease; consistent with Wikipedia.","{'output': 'Below is an overview of Cystic Fibrosis (CF) treatment based on the information we have:\n\n• Airway Clearance Techniques: These are methods (such as chest physiotherapy) used to help loosen and clear thick mucus from the lungs.  \n• Inhaled Medications: These can help thin the mucus, reduce inflammation, and open the airways.  \n• Pancreatic Enzyme Supplements: Since CF can affect the pancreas, enzyme supplements help ensure proper digestion and nutrient absorption.  \n• Nutritional Support: A high-calorie diet is often recommended to support healthy growth and manage the increased energy needs caused by CF.  \n• Exercise: Regular physical activity can help improve lung function and overall fitness.  \n• CFTR Modulators: These advanced therapies address the underlying protein defect (in specific mutations) and can improve lung function and slow disease progression.\n\nPlease consult a specialized CF care team for personalized recommendations and the most up-to-date treatment options.', 'execution_id': '4903', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
W-3,Wikipedia Fallback,What genetic changes cause Tay-Sachs Disease?,"Must state: bi-allelic pathogenic variants in the HEXA gene on chromosome 15 leading to β-hexosaminidase A deficiency; classic infantile, juvenile, adult forms associated with different residual enzyme activities; carrier frequency high in certain populations. No dummy data.","{'output': 'Overview of Tay-Sachs Disease  \n• Tay-Sachs Disease is caused by mutations in the HEXA gene.  \n• The HEXA gene provides instructions for making an enzyme called hexosaminidase A.  \n• Without enough functional hexosaminidase A, a fatty substance called GM2 ganglioside builds up in nerve cells, leading to progressive neurological damage.\n\nInheritance Pattern  \n• Tay-Sachs Disease is inherited in an autosomal recessive pattern. This means that an individual must receive two copies of the altered HEXA gene (one from each parent) to be affected.\n\nPlease let me know if you have any more questions or concerns about Tay-Sachs Disease.', 'execution_id': '4904', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
W-4,Wikipedia Fallback,What is the inheritance pattern of Hemophilia?,"Correct answer: X-linked recessive; Hemophilia A (F8) and B (F9); affected males, carrier females; 50 % chance of passing mutated allele to sons/daughters as per Wikipedia.","{'output': ""Overview of Hemophilia  \nHemophilia (both Hemophilia A and B) is a genetic bleeding disorder caused by defects in certain clotting factors. It primarily affects a person's ability to form blood clots properly.\n\nInheritance Pattern  \n• Hemophilia A and B follow an X-linked recessive inheritance pattern.  \n• Males (who have one X chromosome) are typically affected if they inherit the mutated copy.  \n• Females (who have two X chromosomes) are usually carriers, as they need two copies of the mutation to be affected, which is far less common.\n\nDoes this help clarify your question?"", 'execution_id': '4905', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
W-5,Wikipedia Fallback,How is Alzheimer's Disease diagnosed?,"Should reference clinical criteria (progressive memory impairment affecting activities), supportive biomarkers (CSF Aβ42/tau, amyloid PET), MRI showing medial-temporal atrophy; exclude other dementias; info aligned with Wikipedia.","{'output': 'Hello and welcome! I’m happy to help explain how Alzheimer’s disease is generally diagnosed. Could you share a bit about your concerns or if something in particular prompted this question?\n\nBelow is an overview of the typical diagnostic process:\n\n1. Medical History and Background\n   • A physician reviews personal and family medical history.  \n   • Information about symptom onset, duration, and progression is gathered from the patient and close contacts.\n\n2. Cognitive and Neurological Evaluation\n   • Healthcare providers use standardized tests to assess memory, problem-solving, and language skills.  \n   • A neurological exam (e.g., checking reflexes, muscle tone, and coordination) may also be performed.\n\n3. Imaging Studies\n   • Brain imaging such as MRI or CT scans helps rule out other possible causes of cognitive decline (e.g., stroke or tumors).  \n   • In some cases, specialized imaging like PET scans may be used.\n\n4. Laboratory Tests\n   • Blood tests and other labs help exclude other medical conditions that can affect memory or mimic symptoms of dementia.\n\n5. Clinical Diagnosis\n   • Based on the findings from history, physical exams, cognitive tests, and imaging, a physician can often make a “probable” Alzheimer’s diagnosis.  \n   • A definitive diagnosis can only be confirmed by examining brain tissue after death.\n\nDoes this address your questions about Alzheimer’s diagnosis, or is there anything more you’d like to discuss?', 'execution_id': '4906', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.7,o1-4o
W-6,Wikipedia Fallback,Describe the clinical management of Duchenne Muscular Dystrophy.,"Must cite corticosteroids to slow progression, cardiac surveillance and ACE-inhibitors, ventilatory support incl. nocturnal BiPAP, physiotherapy/orthotics, exon-skipping or gene therapies in development, wheelchair transition planning—per Wikipedia.","{'output': 'Overview of the Condition  \nDuchenne Muscular Dystrophy (DMD) is a genetic disorder that primarily affects muscles, leading to progressive weakness and reduced mobility. Management requires a multidisciplinary approach to address metabolic function, neurological health, and overall quality of life.\n\nKey Management Strategies\n\n1. Metabolic Support  \n   • Dietary modifications tailored to optimize energy production.  \n   • Use of supplements (as recommended) to support cellular metabolism.\n\n2. Neurological Care  \n   • Regular monitoring for any changes in cognitive function.  \n   • Supportive interventions to manage any sensory or cognitive fluctuations.\n\n3. Genetic Counseling  \n   • Discussion of recurrence risks for family planning.  \n   • Guidance to help patients and families make informed decisions about future steps, including genetic testing.\n\n4. Supportive Therapies  \n   • Early educational interventions.  \n   • Physical and occupational therapies to maximize function and developmental outcomes.\n\n5. Informed Consent and Privacy  \n   • Ensuring patients and families understand the benefits and limitations of genetic tests.  \n   • Adhering to relevant privacy regulations regarding genetic information.\n\n6. Long-Term Monitoring  \n   • Ongoing, lifelong follow-up to adjust therapy as the disease progresses.  \n   • Assessment of metabolic and cognitive parameters over time.\n\nBy coordinating care across various healthcare specialties—rehabilitation, neurology, genetics, and social support—an overall strategy can be created to stabilize symptoms, maintain function where possible, and improve long-term outcomes.', 'execution_id': '4907', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.3,o1-4o
W-7,Wikipedia Fallback,What are the genetic risk factors for Down Syndrome?,"Answer: trisomy 21 (95 %), Robertsonian translocation involving chromosome 21 (~4 %), mosaic Down syndrome (~1 %); maternal age as main risk factor; consistent with Wikipedia.","{'output': 'Hello! Thank you for reaching out about genetic risk factors for Down syndrome. Below is a brief overview based on our hospital’s verified resources:\n\nOverview of Down Syndrome (Trisomy 21)\n• Down syndrome is typically caused by having three copies of chromosome 21 instead of the usual two.\n\nPrimary Genetic Risk Factors\n1. Maternal Age:  \n   – The most significant factor. As a mother’s age increases, so does the chance of errors in chromosome division, leading to an extra copy of chromosome 21.  \n2. Translocation Carriers:  \n   – A small number of Down syndrome cases result from a translocation, where chromosome 21 attaches to another chromosome. A parent can be a carrier of this rearrangement without having Down syndrome themselves.\n3. Family History:  \n   – Having another child with Down syndrome (particularly translocation Down syndrome) can slightly increase the risk of having a second child with the condition.\n\nUnderstanding Your Risks\n• Genetic Counseling: If you or your partner suspect a translocation or have a family history of Down syndrome, consulting a genetic counselor can help clarify your family-specific risk.  \n\nI hope this information is helpful. Do you have any particular concerns or additional questions about genetic testing, inheritance, or family planning?', 'execution_id': '4908', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
W-8,Wikipedia Fallback,What is Rett Syndrome and how is it managed?,"Must state MECP2 pathogenic variants on X chromosome; affects girls after 6-18 months; regression of speech/purposeful hand use, stereotypic hand-wringing, seizures; management supportive—physical therapy, anti-epileptics, scoliosis surgery, feeding support. Use Wikipedia facts only.","{'output': 'Below is an overview of Rett Syndrome based on our internal educational materials:\n\nOVERVIEW OF THE CONDITION  \n• Rett Syndrome is a rare genetic neurological disorder that primarily affects females.  \n• It is usually caused by mutations in the MECP2 gene on the X chromosome.  \n• After a period of normal early development, children experience a regression in skills (generally between 6 and 24 months), followed by specific Rett-related challenges.  \n\nKEY FEATURES  \n• Loss of purposeful hand use, replaced by repetitive hand movements (such as wringing or clapping).  \n• Slowed head and brain growth (head circumference growth may slow noticeably).  \n• Difficulty with speaking or reduced verbal skills.  \n• Motor difficulties, including problems walking or coordinating body movements.  \n• Abnormal breathing patterns, including hyperventilation or breath-holding.  \n\nINHERITANCE PATTERNS  \n• Although Rett Syndrome is typically associated with de novo (new) mutations in the MECP2 gene, genetic counseling can help clarify potential recurrence risks or implications for future pregnancies.  \n\nTESTING PROCEDURE  \n• Diagnosis is often based on clinical symptoms and can be confirmed by genetic testing for mutations in the MECP2 gene.  \n• Early recognition of developmental regression and referral to a specialist for further evaluation is crucial.  \n\nMANAGEMENT OPTIONS  \nBecause there is no cure for Rett Syndrome, treatment focuses on easing symptoms and improving quality of life:  \n• Physical therapy to promote mobility and manage joint stiffness or scoliosis.  \n• Occupational therapy to support daily activities and use of adaptive devices.  \n• Speech and communication therapy, often focusing on augmentative or alternative communication methods.  \n• Nutritional support, which may include feeding assistance to ensure adequate calorie intake and proper nutrition.  \n• Medications to control seizures, ease breathing abnormalities, and help with mood or behavior challenges.  \n• Behavioral interventions to address anxiety or mood fluctuations.  \n• Routine monitoring by a multidisciplinary clinical team, including cardiology and gastroenterology as needed.  \n\nETHICAL AND PRIVACY CONSIDERATIONS  \n• Genetic counseling can help families understand the origin of Rett Syndrome and address any concerns about future pregnancies.  \n• Patient privacy and confidentiality are important when sharing genetic information, and families should discuss any questions with their care team.  \n\nResearch is ongoing to identify more targeted treatments. In the meantime, a supportive, team-based approach is key to managing Rett Syndrome and ensuring the best possible quality of life.\n\nI hope this information is helpful. Is there anything else you would like to discuss?', 'execution_id': '4909', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.8,o1-4o
W-9,Wikipedia Fallback,How do you diagnose Wilson Disease?,"Correct response: low ceruloplasmin, high 24-h urinary copper, Kayser–Fleischer rings, ATP7B genetic testing, hepatic copper quantification on biopsy; per Wikipedia.","{'output': 'Overview of Diagnostic Approaches for Wilson Disease\n\n1) Clinical Evaluation\n• Doctors look for classic signs and symptoms, such as liver problems, neurological changes, psychiatric issues, and the presence of Kayser-Fleischer rings (copper deposits in the eyes).\n\n2) Biochemical Tests\n• Serum Ceruloplasmin: Often low because ceruloplasmin does not bind copper properly.\n• Serum Copper: While total serum copper may be low, the “free” (non-ceruloplasmin-bound) copper is typically elevated.\n• 24-Hour Urinary Copper Excretion: Higher-than-normal levels of copper in urine are a key indicator.\n\n3) Liver Function Tests\n• These help assess any damage or inflammation in the liver, which is commonly affected by the copper buildup.\n\n4) Genetic Testing\n• Testing for mutations in the ATP7B gene can confirm the diagnosis.\n\n5) Liver Biopsy\n• In certain cases, measuring how much copper is stored in the liver can provide more definitive evidence.\n\n6) Imaging\n• A brain MRI may identify characteristic changes when neurological symptoms are present.\n\nThese evaluations, taken together, give doctors a clear picture for confirming Wilson disease. Please let me know if you have any follow-up questions or concerns about this information.', 'execution_id': '4910', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
W-10,Wikipedia Fallback,What are common symptoms of Noonan Syndrome?,"Should list short stature, webbed neck, ptosis/hypertelorism, congenital heart defects (pulmonary valve stenosis), pectus excavatum, coagulation defects, learning difficulties—as described on Wikipedia.","{'output': 'Overview of Noonan Syndrome Symptoms:\n\n• Distinctive Facial Features  \n  - Wide-set eyes  \n  - Low-set ears  \n  - Thick or webbed neck  \n\n• Heart Defects  \n  - Pulmonary valve stenosis is the most common  \n\n• Growth and Development  \n  - Short stature (may be noticeable in childhood)  \n  - Developmental delays (ranging from mild to more significant)\n\n• Chest and Skeletal Differences  \n  - Chest deformities (such as pectus excavatum or carinatum)  \n  - Skeletal malformations  \n\n• Additional Symptoms  \n  - Bleeding problems  \n  - Occasional learning difficulties  \n\nSymptoms can vary notably from person to person in their type and severity. If you or a loved one suspect Noonan Syndrome, it’s best to consult with a healthcare professional for an evaluation and personalized guidance.', 'execution_id': '4911', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
N-1,Missing Information Handling,What are the key features of Phantom Syndrome?,Must state no reliable information found in any source and refuse to fabricate clinical details.,"{'output': 'I’m sorry, but I couldn’t find any information in our available references about “Phantom Syndrome.”', 'execution_id': '4912', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-2,Missing Information Handling,Explain the diagnosis of Mirage Disorder X.,"Answer should state no data available in protocol, GeneReviews, or Wikipedia; must not invent diagnostic criteria.","{'output': 'Hello! Thank you for reaching out. I’m not finding any recognized references or published information in our resources for “Mirage Disorder X.” Could you share more details about your symptoms or reasons for concern? I’d be happy to learn more and see how else I might help.', 'execution_id': '4913', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-3,Missing Information Handling,How is Nebula Disorder inherited?,Should acknowledge lack of information and avoid speculation about inheritance pattern.,"{'output': 'I’m sorry, but I couldn’t find any information about Nebula Disorder or its inheritance pattern in our available resources. Could you please provide any additional details you may have or double-check the name of the condition? I want to ensure I have the correct information to help you.', 'execution_id': '4914', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-4,Missing Information Handling,What are the treatment options for Stellar Syndrome?,Must respond that no authoritative information exists and therefore treatments cannot be advised.,"{'output': 'Hello! I’m sorry, but I’m not finding anything in our resources regarding “Stellar Syndrome.” Could you share any additional details about this condition—such as the symptoms, how it was diagnosed, or any alternative names you’ve come across? That might help me locate more specific information.', 'execution_id': '4915', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
N-5,Missing Information Handling,Describe the clinical presentation of Twilight Syndrome.,Must report no available data; should not fabricate symptoms.,"{'output': 'Hello, and thank you for your question about Twilight Syndrome. \n\nI wasn’t able to locate any official medical information or recognized descriptions of a condition referred to as “Twilight Syndrome” in our verified resources. It’s possible that the term might be informal or uncommon. Could you share any additional details you’ve come across—such as symptoms, test results, or another name for the condition? That might help us investigate further and provide more accurate information.\n\nPlease let me know if you have any further details, and I’ll do my best to guide you.', 'execution_id': '4916', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-6,Missing Information Handling,What is the molecular basis of Eosphorus Disorder?,Should state no molecular data found; do not fabricate gene names.,"{'output': 'I’m sorry, but I don’t have any information on “Eosphorus Disorder” or its molecular basis in our records. I recommend discussing further with a genetic counselor or specialist who may have more details or be able to guide you to additional resources.', 'execution_id': '4917', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-7,Missing Information Handling,List the symptoms of Arcadia Syndrome.,Must refuse to invent symptoms and clearly state no information exists.,"{'output': 'I’m sorry, but none of our available sources (internal protocols, GeneReviews, and Wikipedia) provide any information about a condition called “Arcadia Syndrome.” If you believe this syndrome could be relevant to you, please double-check the name or consider consulting a medical professional for further guidance.\n\nIs there anything else I can help you with today?', 'execution_id': '4918', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-8,Missing Information Handling,What are the genetic markers for Lumenopathy?,Answer must say genetic markers unknown or not documented in any reputable source.,"{'output': 'I’m sorry, but I couldn’t find any information regarding a condition called “Lumenopathy” or its genetic markers in our verified resources. It may be that this information isn’t yet documented in our system. \n\nIf you have more details or if you suspect a different condition name, feel free to let me know so I can research further. Otherwise, I recommend discussing this with a genetic specialist who might have access to additional or more up-to-date resources.', 'execution_id': '4919', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-9,Missing Information Handling,How do you manage Monoculus Syndrome?,Must respond that management guidelines are nonexistent due to lack of information.,"{'output': 'I’m sorry, but I couldn’t find any information on “Monoculus Syndrome” in our available references and databases. It’s possible that the name is very rare or might be spelled differently. Can you provide any additional details or clarify the name of the condition? \n\nIs there anything else you’d like to discuss?', 'execution_id': '4920', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
N-10,Missing Information Handling,Explain the inheritance of Prismatic Disorder.,Should acknowledge no data on inheritance and avoid guessing.,"{'output': 'I’m sorry, but I couldn’t find any references in our available resources about a condition called “Prismatic Disorder.” It may not be a recognized medical condition or could be referenced under a different name. \n\nDo you have more details or other names for this condition? If so, please let me know, and I will try to locate specific information for you.', 'execution_id': '4921', 'to_agent': 'patient_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
R-1,Referrals to Other Agents,Can you help me schedule a follow-up appointment for my child?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent' (or ends with <SCHEDULING>).,"{'output': 'Can you help me schedule a follow-up appointment for my child?', 'execution_id': '4922', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
R-2,Referrals to Other Agents,How do I update my insurance information?,Pass if the agent routes to administrative and outputs to_agent: 'administrative_agent' (or ends with <ADMIN>).,"{'output': 'How do I update my insurance information?', 'execution_id': '4923', 'to_agent': 'administrative_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
R-3,Referrals to Other Agents,I want to know the clinic’s opening hours.,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent' (or ends with <FRONT_DESK>).,"{'output': 'I want to know the clinic’s opening hours.', 'execution_id': '4924', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
R-4,Referrals to Other Agents,Can you connect me with a genetic counselor for a family planning session?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent'.,"{'output': 'I’ll forward your request to our scheduling agent so they can assist you further with booking an appointment.', 'execution_id': '4925', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
R-5,Referrals to Other Agents,How do I get a copy of my lab results?,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent' or ends with <FRONT_DESK>.,"{'output': 'I’ll forward your request regarding obtaining a copy of your lab results to our front-desk agent for further assistance.', 'execution_id': '4926', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
R-6,Referrals to Other Agents,Can I reschedule my appointment?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent'.,"{'output': '', 'execution_id': '4927', 'to_agent': 'scheduling_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
R-7,Referrals to Other Agents,Who should I contact to change my address in the system?,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent' or ends with <FRONT_DESK>.,"{'output': 'Who should I contact to change my address in the system?', 'execution_id': '4928', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
R-8,Referrals to Other Agents,What insurance plans does this clinic accept?,Pass if the agent routes to administrative and outputs to_agent: 'administrative_agent'.,"{'output': 'What insurance plans does this clinic accept?', 'execution_id': '4929', 'to_agent': 'administrative_agent', 'from_agent': 'education_agent', 'end_conversation': False}",1.0,o1-4o
R-9,Referrals to Other Agents,I need directions to the clinic.,Pass if the agent routes to front-desk and outputs to_agent: 'frontdesk_agent'.,"{'output': 'I need directions to the clinic.', 'execution_id': '4930', 'to_agent': 'frontdesk_agent', 'from_agent': 'education_agent', 'end_conversation': False}",0.9,o1-4o
R-10,Referrals to Other Agents,How do I cancel my appointment?,Pass if the agent routes to scheduling and outputs to_agent: 'scheduling_agent'.,{'output': 'Error: 500 Server Error: Internal Server Error for url: https://congliu.app.n8n.cloud/webhook/bdfcc15d-a70c-4fb4-9df6-5beaf18fa2d6'},0.0,o1-4o
